Author Index to Volume 42*

A

Abdalla EK (*see* Pawlik TM et al). 2005;42:738-739 (Correspondence)
Abdei-Aziz F (*see* Mohamed MK et al). 2005;42:683-687
Abdel-Hamid M (*see* Mohamed MK et al). 2005;42:683-687
Abrams GA, Clements RH, Lazenby AJ. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. 2005;42:1461 (Reply)
Abrams GA (*see* Kunde SS et al). 2005;42:650-656
Accornero N (*see* Riggio O et al). 2005;42:1158-1165
Acute Liver Failure Study Group (*see* Larson AM et al). 2005;42:1364-1372
Ajuebor MN (*see* Zhou F et al). 2005;42:372-380
Akashi S (*see* Kuzumoto Y et al). 2005;42:608-617
Albillos A (*see* Muñoz L et al). 2005;42:411-419
Aleffi S, Petrai I, Bertolani C, Parola M, Colombatto S, Novo E, Vizzutti F, Anania FA, Milani S, Rombouts K, Laffi G, Pinzani M, Marra F. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells. 2005;42:1339-1348
Allander T (*see* Schofield DJ et al). 2005;42:1055-1062
Alter HJ. Hepatology Highlights. 2005;42:1-3, 745-747
— (*see* Schofield DJ et al). 2005;42:1055-1062
Altug-Teber Ö (*see* Stahl S et al). 2005;42:353-361
Alvarez F (*see* Marceau G et al). 2005;42:675-682
Alvarez-Mon M (*see* Muñoz L et al). 2005;42:411-419
Amaral JD (*see* Solá S et al). 2005;42:925-934
Anan A and Gores GJ. A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome. 2005;42:527-529 (Editorial)
Anania FA. Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? 2005;42:530-532 (Editorial)
Anania FA (*see* Aleffi S et al). 2005;42:1339-1348
Anderson J (*see* Wang G et al). 2005;42:871-879
Andrews WW (*see* Mosley JW et al). 2005;42:86-92
Angeloni S (*see* Riggio O et al). 2005;42:1158-1165
Angulo P (*see* Zein CO et al). 2005;42:762-771
Ansari AA (*see* Mao TK et al). 2005;42:802-808
Aoki T (*see* Nagakawa Y et al). 2005;42:208-215
Arenovich T (*see* Feld JJ et al). 2005;42:53-62
Arnaud C (*see* Taïeb D et al). 2005;42:176-182
Arocena C (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
— (*see* Clària J and Arroyo V). 2005;42:238 (Reply)
— (*see* Fernández J et al). 2005;42:627-634
— (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Arvelo MB (*see* Longo CR et al). 2005;42:156-164
Ashwood P (*see* Mao TK et al). 2005;42:802-808
Attili AF (*see* Riggio O et al). 2005;42:1158-1165
Aubert D (*see* Bellodi-Privato M et al). 2005;42:431-438
Averett DR (*see* Horsmans Y et al). 2005;42:724-731

B

Baba M (*see* Kato N et al). 2005;42:846-853
Baczkowski A (*see* González-Peralta RP et al). 2005;42:1010-1018
Balistreri WF, Bezerra JA, Jansen P, Karpen SJ, Shneider BL, Suchy FJ. Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference. 2005;42:222-235 (Special Article)
Ballatori N, Christian WV, Lee JY, Dawson PA, Soroka CJ, Boyer JL, Madejczyk MS, Li N. OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia. 2005;42:1270-1279
Bañares R and Núñez O. Influence of TIPS on development of hepatocellular carcinoma in cirrhosis. 2005;42:236-237 (Reply)
Bañares R (*see* Ripoll C et al). 2005;42:793-801
Bantel H (*see* Seidel N et al). 2005;42:113-120
Bao D (*see* Yu XX et al). 2005;42:362-371
Baranova A (*see* Younossi ZM et al). 2005;42:665-674
Barbu V (*see* Chignard N et al). 2005;42:549-557
Bargallo X (*see* Fernández J et al). 2005;42:627-634
Barnes DS (*see* Combes B et al). 2005;42:1184-1193
Bartosch B (*see* Schofield DJ et al). 2005;42:1055-1062
Baskin-Bey E (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Bass NM (*see* Combes B et al). 2005;42:1184-1193
Batteux F (*see* Lieu HT et al). 2005;42:618-626
Battjes RJ (*see* Hisada M et al). 2005;42:1446-1452
Baum H (*see* Bogdanos DP et al). 2005;42:458-465
Bauman LA (*see* Horsmans Y et al). 2005;42:724-731
Baumert TF, Köck J, Blum HE. A novel target of hepatitis B virus mutations: splicing of surface RNA. 2005;42:21-23 (Editorial)
— (*see* Rösler C et al). 2005;42:301-309
Beard MR (*see* Helbig KJ et al). 2005;42:702-710
— (*see* Lau DTY et al). 2005;42:273-281
Beck PL (*see* Zhou F et al). 2005;42:372-380
Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study. 2005;42:44-52
Behling C (*see* Schwimmer JB et al). 2005;42:641-649
Béland K (*see* Marceau G et al). 2005;42:675-682
Belghiti J (*see* Pawlik TM et al). 2005;42:738-739 (Correspondence)
Bellentani S (*see* Bedogni G et al). 2005;42:44-52
Bellodi-Privato M, Aubert D, Pichard V, Myara A, Trivin F, Ferry N. Successful gene therapy of the Gunn rat by *in vivo* neonatal hepatic gene transfer using murine oncoretroviral vectors. 2005;42:431-438
Beltroy EP, Richardson JA, Horton JD, Turley SD, Dietschy JM. Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease. 2005;42:886-893
Benedetti A (*see* Svegliati-Baroni G et al). 2005;42:343-352

*July, 1-246; August, 247-510; September, 511-744; October, 745-984; November 985-1240; December, 1241-1512.

Benner KG (*see* Combes B et al). 2005;42:1184-1193
Benten D, Follenzi A, Bhargava KK, Kumaran V, Palestro CJ, Gupta S. Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice. 2005;42:140-148
—, Kumaran V, Joseph B, Schattenberg J, Popov Y, Schuppan D, Gupta S. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat. 2005;42:1072-1081
Beraza N (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Berg T. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. 2005;42:1459-1460 (Reply)
— (*see* Horsmans Y et al). 2005;42:724-731
— (*see* van Bömmel F and Berg T). 2005;42:239-240 (Correspondence)
Berke JM and Moradpour D. Hepatitis C virus comes full circle: production of recombinant infectious virus in tissue culture. 2005;42:1264-1269 (Science Frontier)
Bertolani C (*see* Aleffi S et al). 2005;42:1339-1348
Bertolino P, Schrage A, Bowen DG, Klugewitz K, Ghani S, Eulenburg K, Holz L, Hogg N, McCaughan GW, Hamann A. Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice. 2005;42:1063-1071
Beyaert R (*see* Wullaert A et al). 2005;42:381-389
Bezerra JA (*see* Balistreri WF et al). 2005;42:222-235 (Special Article)
Bhanot S (*see* Yu XX et al). 2005;42:362-371
Bhargava KK (*see* Benten D et al). 2005;42:140-148
Billiar TR (*see* Chen T et al). 2005;42:598-607
— (*see* Lagoa CE et al). 2005;42:390-399
Bini EJ (*see* Shim M et al). 2005;42:688-695
Bird SM (*see* Hutchinson SJ et al). 2005;42:711-723
Biroli G (*see* Musso G et al). 2005;42:1175-1183
Björnsson E and Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. 2005;42:481-489
Blei AT. Who writes the article? 2005;42:511 (Editor's Corner)
Bleier JI (*see* Katz SC et al). 2005;42:293-300
Blum HE (*see* Baumert TF et al). 2005;42:21-23 (Editorial)
— (*see* Rösler C et al). 2005;42:301-309
— (*see* Spangenberg HC et al). 2005;42:828-837
Bodenheimer H Jr (*see* Schiano TD et al). 2005;42:1420-1428
Bodian C (*see* Schiano TD et al). 2005;42:1420-1428
Bogaert V (*see* Wullaert A et al). 2005;42:381-389
Bogdanos DP, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, Vlachogiannakos J, Ma Y, Burroughs AK, Vergani D. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic. 2005;42:458-465
Bolondi L, Gaiani S, Celli N, Golfieri R, Grigioni WF, Leoni S, Venturi AM, Piscaglia F. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. 2005;42:27-34
Bonacini M (*see* Combes B et al). 2005;42:1184-1193
Bonin M (*see* Stahl S et al). 2005;42:353-361
Bonkovsky HL (*see* Lok ASF et al). 2005;42:282-292
Booten SL (*see* Yu XX et al). 2005;42:362-371
Borel Rinkes IHM (*see* van der Bilt JDW et al). 2005;42:165-175
Born TL (*see* Younossi ZM et al). 2005;42:665-674
Borque MJ (*see* Salcedo X et al). 2005;42:696-701
Borralho PM (*see* Solá S et al). 2005;42:925-934
Borst P (*see* Manautou JE et al). 2005;42:1091-1098
Bosch J (*see* Fernández J et al). 2005;42:627-634
Bostrom A (*see* Monto A et al). 2005;42:310-316
Bowen DG (*see* Bertolino P et al). 2005;42:1063-1071
Boyer JL (*see* Ballatori N et al). 2005;42:1270-1279
— (*see* Combes B et al). 2005;42:1184-1193
Boyer TD. TIPS for veno-occlusive disease: Is the contraindication real? 2005;42:241 (Reply)
— (*see* Combes B et al). 2005;42:1184-1193
Bradford BU (*see* Powell CL et al). 2005;42:1137-1147
Brady CW and Muir AJ. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 2005;42:496-497 (Correspondence)
Branch AD (*see* Schiano TD et al). 2005;42:1420-1428
Brandenburg B, Stockl L, Gutzeit C, Roos M, Lupberger J, Schwartlander R, Gelderblom H, Sauer IM, Hofschneider PH, Hildt E. A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle. 2005;42:1300-1309
Brass V (*see* Moradpour D et al). 2005;42:732-735 (Hepatology *Elsewhere*)
Bréchot C (*see* Lieu HT et al). 2005;42:618-626
Brenner DA (*see* Osawa Y et al). 2005;42:1320-1328
Brensinger CM (*see* Campbell MS et al). 2005;42:635-640
Brind A (*see* Forrest E et al). 2005;42:495 (Correspondence)
Bronk SF (*see* Isomoto H et al). 2005;42:1329-1338
Bruix J and Sherman M. Management of hepatocellular carcinoma. 2005;42:1208-1236 (AASLD Practice Guideline)
Buard J (*see* Guettier C et al). 2005;42:35-43
Buchmann A (*see* Stahl S et al). 2005;42:353-361
Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: a metabolic pathway to chronic liver disease. 2005;42:987-1000 (Concise Review in Mechanisms of Disease)
— (*see* Villanova N et al). 2005;42:473-480
Bukh J (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Burczynski FJ (*see* Wang G et al). 2005;42:871-879
Burdelski M (*see* Keitel V et al). 2005;42:978 (Reply)
Burgart LJ (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Burroughs AK (*see* Bogdanos DP et al). 2005;42:458-465
— (*see* Senzolo M et al). 2005;42:240-241 (Correspondence)
Busch MP (*see* Mosley JW et al). 2005;42:86-92

C

Cai X (*see* Zeng MD et al). 2005;42:1437-1445
Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konaté A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. 2005;42:1373-1381
Calvisi DF (*see* Pascale RM et al). 2005;42:1310-1319
Campbell MS, Brensinger CM, Sanyal AJ, Gennings C, Wong F, Kowdley KV, McCashland T, Reddy KR. Quality of life in refractory ascites: transjugular intrahepatic portal-

systemic shunting versus medical therapy. 2005;42:635-640
— and Makar GA. Safety of short-term administration of celecoxib in decompensated cirrhosis. 2005;42: 237 (Correspondence)
Carelloo M (*see* Musso G et al). 2005;42: 1175-1183
Carithers RL Jr (*see* Combes B et al). 2005; 42:1184-1193
Caron P (*see* Girard H et al). 2005;42:448-457
Cassader M (*see* Musso G et al). 2005;42: 1175-1183
Castro RE (*see* Solá S et al). 2005;42:925-934
Catalano C (*see* Riggio O et al). 2005;42: 1158-1165
Catalina MV (*see* Ripoll C et al). 2005;42: 793-801
Cederbaum AI (*see* Wang X et al). 2005; 42:400-410
Celli N (*see* Bolondi L et al). 2005;42:27-34
Chandhoke V (*see* Younossi ZM et al). 2005;42:665-674
Chatterjee N (*see* Hisada M et al). 2005;42: 1446-1452
Chaudhry UI (*see* Katz SC et al). 2005;42: 293-300
Chayama K (*see* Tsuge M et al). 2005;42: 1046-1054
Chen CW (*see* Zeng MD et al). 2005;42: 1437-1445
Chen MF (*see* Yeh TS et al). 2005;42:657-664
Chen S (*see* Yu XX et al). 2005;42:362-371
Chen T, Pearce LL, Peterson J, Stoyanovsky D, Billiar TR. Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity. 2005;42: 598-607
Chen TC (*see* Yeh TS et al). 2005;42:657-664
Chen YQ (*see* Nierhoff D et al). 2005;42: 130-139
Cheng B (*see* Schiano TD et al). 2005;42: 1420-1428
Cheng JH (*see* Deng Q et al). 2005;42: 905-914
Chevailler A (*see* Calès P et al). 2005;42: 1373-1381
Chignard N, Mergey M, Barbu V, Finzi L, Tiret E, Paul A, Housset C. VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium. 2005;42:549-557
Chin AC (*see* Djojosubroto MW et al). 2005;42:1127-1136
Chiu CT (*see* Yeh TS et al). 2005;42:657-664
Chokshi S (Rigopoulou EI et al). 2005;42: 1028-1036
Cholongitas E (*see* Senzolo M et al). 2005; 42:240-241 (Correspondence)
Chong WP, To YF, Ip WK, Yuen MF, Poon TP, Wong WHS, Lai CL, Lau YL. Mannose-binding lectin in chronic hepatitis B virus infection. 2005;42:1037-1045
Christa L (*see* Lieu HT et al). 2005;42:618-626
Christian WV (*see* Ballatori N et al). 2005; 42:1270-1279
Chrysagis D (*see* Sypsa VA et al). 2005;42: 77-85
Chung RT (*see* Schiano TD et al). 2005; 42:1420-1428
Clària J and Arroyo V. Safety of short-term administration of celecoxib in decompensated cirrhosis. 2005;42: 238 (Reply)
Clarke B (*see* Zein CO et al). 2005;42:762-771
Clemens DL (*see* Osna NA et al). 2005;42: 1109-1117
Clemente G (*see* Ripoll C et al). 2005;42: 793-801
Clements RH (*see* Abrams GA et al). 2005; 42:1461 (Reply)
— (*see* Kunde SS et al). 2005;42:650-656
Clerici C (*see* Hofmann AF et al). 2005;42: 1391-1398
Clouston AD (*see* Powell EE et al). 2005; 42:5-13 (Perspectives in Clinical Hepatology)
Cogger VC (*see* Hilmer SN et al). 2005;42: 1349-1354
Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. 2005;42:838-845
Colli A (*see* Prati D et al). 2005;42:1460-1461 (Correspondence)
Colombatto S (*see* Aleffi S et al). 2005;42: 1339-1348
Colombo M (*see* Lampertico P et al). 2005; 42:1414-1419
— (*see* Prati D et al). 2005;42:1460-1461 (Correspondence)
Columbano A, Ledda-Columbano GM, Pibiri M, Cossu C, Menegazzi M, Moore DD, Huang W, Tian J, Locker J. Gadd45β is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia. 2005;42:1118-1126
Combes B, Emerson SS, Flye NL, Munoz SJ, Luketic VA, Mayo MJ, McCashland TM, Zetterman RK, Peters MG, Di Bisceglie AM, Benner KG, Kowdley KV, Carithers RL Jr, Rosoff L Jr, Garcia-Tsao G, Boyer JL, Boyer TD, Martinez EJ, Bass NM, Lake JR, Barnes DS, Bonacini M, Lindsay KL, Mills AS, Markin RS, Rubin R, West AB, Wheeler DE, Contos MJ, Hofmann AF. Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. 2005;42:1184-1193
—. Reflections on therapeutic trials in primary biliary cirrhosis. 2005;42: 1009 (Editorial)
Combet C (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Conjeevaram HS (*see* Marrero JA et al). 2005;42:739-740 (Reply)
Considine RV (*see* You M et al). 2005;42: 568-577
Conte D (*see* Prati D et al). 2005;42:1460-1461 (Correspondence)
Contos MJ (*see* Combes B et al). 2005;42: 1184-1193
Coppel RL (*see* Mao TK et al). 2005;42: 802-808
Corkill M (*see* Feranchak AP et al). 2005; 42:782-792
Cortes A (*see* Lieu HT et al). 2005;42:618-626
Cosset EL (*see* Schofield DJ et al). 2005;42: 1055-1062
Cosset FL (*see* Youn YW et al). 2005;42: 1429-1436
Cossu C (*see* Columbano A et al). 2005;42: 1118-1126
Costa RH, Kalinichenko VV, Tan Y, Wang IC. The CAR nuclear receptor and hepatocyte proliferation. 2005; 42:1004-1008 (Editorial)
Costi R , Violi V, Roncoroni L, Sarli L. Small gallstones and pancreatitis. 2005;42:736 (Correspondence)
Cotecchia S (*see* Sarang Z et al). 2005;42: 578-587
Coulouarn C, Lefebvre G, Daveau R, Letellier F, Hiron M, Drouot L, Daveau M, Salier JP. Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation. 2005;42:946-955
Court MH (*see* Girard H et al). 2005;42: 448-457
Cox AL, Mosbruger T, Lauer GM, Pardoll D, Thomas DL, Ray SC. Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C. 2005;42:104-112
Cox TM (*see* Zoller H et al). 2005;42:466-472
Crabb DW (*see* You M et al). 2005;42: 568-577
Csizmadia E (*see* Longo CR et al). 2005;42: 156-164

D

Dagorn JC (*see* Taïeb D et al). 2005;42: 176-182
Daino L (*see* Pascale RM et al). 2005;42: 1310-1319
Dandri M and Petersen J. Hepatitis B virus cccDNA clearance: killing for curing?

2005;42:1453-1455 (Hepatology *Elsewhere*)
Daniel S (*see* Longo CR et al). 2005;42: 156-164
Daveau M (*see* Coulouarn C et al). 2005; 42:946-955
Daveau R (*see* Coulouarn C et al). 2005; 42:946-955
Davern TJ (*see* Larson AM et al). 2005;42: 1364-1372
Dawson PA (*see* Ballatori N et al). 2005;42: 1270-1279
Day C (*see* Forrest E et al). 2005;42:495 (Correspondence)
De Geest B (*see* Wullaert A et al). 2005;42: 381-389
de Jong KP (*see* Geuken E et al). 2005;42: 1166-1174
de la Hera A (*see* Muñoz L et al). 2005;42: 411-419
De Michieli F (*see* Musso G et al). 2005; 42:1175-1183
De Miglio MR (*see* Pascale RM et al). 2005;42:1310-1319
De Re V (*see* Sansanno D et al). 2005;42: 1019-1027
de Waart DR (*see* Manautou JE et al). 2005;42:1091-1098
DeAngelis RA, Markiewski MM, Taub R, Lambris JD. A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα. 2005;42:1148-1157
Del Giacco L (*see* Younossi ZM et al). 2005;42:665-674
Deléage G (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
DeMatteo RP (*see* Katz SC et al). 2005;42: 293-300
Demeilliers C (*see* Robin MA et al). 2005; 42:1280-1290
Denda A (*see* Powell CL et al). 2005;42: 1137-1147
Deng Q, She H, Cheng JH, French SW, Koop DR, Xiong S, Tsukamoto H. Steatohepatitis induced by intragastric overfeeding in mice. 2005;42:905-914
Denk H (*see* Wagner M et al). 2005;42: 420-430
Dent P, Fang Y, Gupta S, Studer E, Mitchell C, Spiegel S, Hylemon PB. Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes. 2005;42: 1291-1299
Desager JP (*see* Horsmans Y et al). 2005; 42:724-731
Deutsch R (*see* Schwimmer JB et al). 2005; 42:641-649
Devière J (*see* Moreno C et al). 2005;42: 854-862
Dezs[font"MS Reference 1"]ō[/font"MS Reference 1"] K (*see* Paku S et al). 2005;42:863-870
Dharel N (*see* Kato N et al). 2005;42:846-853
Dhumeaux D (*see* Hézode C et al). 2005; 42:63-71
Di Bisceglie AM (*see* Combes B et al). 2005;42:1184-1193
— (*see* Lok ASF et al). 2005;42:282-292
Diehl AM (*see* Li Z et al). 2005;42:880-885
Dienstag JL (*see* Lok ASF et al). 2005;42: 282-292
Dietrich CG and Geier A. It takes more than one—Is a single UGT polymorphism enough to bother detoxification? 2005;42:1462 (Correspondence)
Dietschy JM (*see* Beltroy EP et al). 2005; 42:886-893
Dimakopoulos K (*see* Papatheodoridis GV et al). 2005;42:121-129
Dimou E (*see* Papatheodoridis GV et al). 2005;42:121-129
Dinh H (*see* Feld JJ et al). 2005;42:53-62
Djojosubroto MW, Chin AC, Go N, Schaetzlein S, Manns MP, Gryaznow S, Harley CB, Rudolph KL. Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma. 2005;42:1127-1136
Dockter J (*see* Mosley JW et al). 2005;42: 86-92
Donoue TM Jr (*see* Osna NA et al). 2005; 42:1109-1117
Doo E (*see* Ghany MG and Doo E). 2005; 42:759-761 (Editorial)
Douglas SD (*see* Zhang T et al). 2005;42: 819-827
Dove LM (*see* Monto A et al). 2005;42: 310-316
Drammacco F (*see* Sansanno D et al). 2005;42:1019-1027
Drouot L (*see* Coulouarn C et al). 2005;42: 946-955
Dubois S (*see* Robin MA et al). 2005;42: 1280-1290
Dunn W, Kamath PS, Wiesner RH, Kim WR, Shah V. Grading alcoholic hepatitis. 2005;42:495-496 (Reply)
Durazzo M (*see* Musso G et al). 2005;42: 1175-1183

E

Ebata K (*see* Nakayama Y et al). 2005;42: 915-924
Efrati C (*see* Riggio O et al). 2005;42: 1158-1165
El Bakkouri K (*see* Wullaert A et al). 2005; 42:381-389
Elariny H (*see* Younossi ZM et al). 2005; 42:665-674
Elferink RO (*see* Manautou JE et al). 2005; 42:1091-1098
Elias E. Hepatology Highlights. 2005;42: 512-513, 1241-242
Else C (*see* Svegliati-Baroni G et al). 2005; 42:343-352
Embree-Ku M and Gruppuso PA. The role of nuclear factor κB in late-gestation development in the rat. 2005;42:326-334
Emerson SS (*see* Combes B et al). 2005;42: 1184-1193
Emerson SU (*see* Schofield DJ et al). 2005; 42:1055-1062
Enomoto N (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Eulenburg K (*see* Bertolino P et al). 2005; 42:1063-1071
Everhart JE (*see* Lok ASF et al). 2005;42: 282-292
Everson GT, Trotter J, Fórman L, Kugelmas M, Halprin A, Fey B, Ray C. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. 2005;42: 255-262 (Rapid Communication)
— (*see* Lok ASF et al). 2005;42:282-292

F

Fabris C (*see* Colletta C et al). 2005;42: 838-845
Fagà E (*see* Musso G et al). 2005;42:1175-1183
Fan ST (*see* Tsui TY et al). 2005;42:335-342
Fang Y (*see* Dent P et al). 2005;42:1291-1299
Farkas S (*see* Tsui TY et al). 2005;42:335-342
Feinstone S (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Feld J and Heathcote EJ. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? 2005;42: 1237-1238 (Reply)
Feld JJ, Dinh H, Arenovich T, Marcus VA, Wanless IR, Heathcote EJ. Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome. 2005;42:53-62
Feneux D (*see* Guettier C et al). 2005;42: 35-43
Feo F (*see* Pascale RM et al). 2005;42: 1310-1319
Feranchak AP, Gralla J, King R, Ramirez RO, Corkill M, Narkewicz MR, Sokol RJ. Comparison of indices of vitamin A status in children with chronic liver disease. 2005;42:782-792
Féray C (*see* Guettier C et al). 2005;42:35-43
Ferber MJ (*see* Perri RE et al). 2005;42:974 (Correspondence)
Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, Navasa M. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. 2005;42:627-634

Ferran C (*see* Longo CR et al). 2005;42:156-164
Ferry N (*see* Bellodi-Privato M et al). 2005;42:431-438
Fésüs L (*see* Sarang Z et al). 2005;42:578-587
Fevery J (*see* Laleman W et al). 2005;42:1382-1390
Fey B (*see* Everson GT et al). 2005;42:255-262 (Rapid Communication)
Fickert P (*see* Wagner M et al). 2005;42:420-430
Fiel MI (*see* Schiano TD et al). 2005;42:1420-1428
Fink MP (*see* Lagoa CE et al). 2005;42:390-399
Finzi L (*see* Chignard N et al). 2005;42:549-557
Fiorucci S, Antonelli E, Mencarelli A, Orlandi S, Renga B, Rizzo G, Distrutti E, Shah V, Morelli A. The third gas: H_2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis. 2005;42:539-548
Fisher N (*see* Forrest E et al). 2005;42:495 (Correspondence)
Fix AD (*see* Mohamed MK et al). 2005;42:683-687
Flemming P (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Fletecher SP (*see* Horsmans Y et al). 2005;42:724-731
Flye NL (*see* Combes B et al). 2005;42:1184-1193
Follenzi A (*see* Benten D et al). 2005;42:140-148
Fontana RJ (*see* Larson AM et al). 2005;42:1364-1372
— (*see* Marrero JA et al). 2005;42:739-740 (Reply)
Forman L (*see* Everson GT et al). 2005;42:255-262 (Rapid Communication)
Forns X. HCV: alive and kicking in living donor liver grafts? 2005;42:1258-1260 (Editorial)
Forrest E, Singhal S, Haydon G, Day C, Fisher N, Brind A, Hayes P. Grading alcoholic hepatitis. 2005;42:495 (Correspondence)
Fortier LC (*see* Girard H et al). 2005;42:448-457
Frank DA (*see* Isomoto H et al). 2005;42:1329-1338
Fraser R (*see* Hilmer SN et al). 2005;42:1349-1354
Frau M (*see* Pascale RM et al). 2005;42:1310-1319
Freitag CM (*see* Höhler T et al). 2005;42:72-76
French SW (*see* Deng Q et al). 2005;42:905-914
Frenzel C (*see* Wiegard C et al). 2005;42:193-199
Fromenty B (*see* Robin MA et al). 2005;42:1280-1290
Fujimoto Y (*see* Tsuge M et al). 2005;42:1046-1054
Furukawa T (*see* Yamauchi K et al). 2005;42:149-155

G

Gaiani S (*see* Bolondi L et al). 2005;42:27-34
Gallo D (*see* Lagoa CE et al). 2005;42:390-399
Gallois Y (*see* Calès P et al). 2005;42:1373-1381
Gambino R (*see* Musso G et al). 2005;42:1175-1183
Ganten TM, Koschny R, Haas TL, Sykora J, Li-Weber M, Kerzer K, Walczak H. Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL. 2005;42:588-597
— (*see* Herzer K et al). 2005;42:183-192
Ganz T (*see* Zoller H et al). 2005;42:466-472
Gao CF (*see* Zeng MD et al). 2005;42:1437-1445
Garcia S (*see* Taïeb D et al). 2005;42:176-182
García-Buey L (*see* Salcedo X et al). 2005;42:696-701
García-García JA (*see* Pineda JA and García-García JA). 2005;42:497 (Reply)
Garcia-Tsao G (*see* Combes B et al). 2005;42:1184-1193
Gebel M (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Geffner M (*see* González-Peralta RP et al). 2005;42:1010-1018
Geier A (*see* Dietrich CG and Geier A). 2005;42:1462 (Correspondence)
Gelderblom H (*see* Brandenburg B et al). 2005;42:1300-1309
Gennings C (*see* Campbell MS et al). 2005;42:635-640
Gershwin ME, Selmi C, Worman HJ, Gold EB, Watnik M, Utts J, Lindor KD, Kaplan MM, Vierling JM, USA PBC Epidemiology Group. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. 2005;42:1194-1202
— (*see* Mao TK et al). 2005;42:802-808
Geuken E, Visser DS, Leuvenink HGD, de Jong KP, Peeters PMJG, Slooff MJH, Kuipers F, Porte RJ. Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients. 2005;42:1166-1174
Ghani S (*see* Bertolino P et al). 2005;42:1063-1071
Ghanta RK and Mullen KD. Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical. 2005;42:1206-1207 (Hepatology *Elsewhere*)
Ghany MG (*see* Lok ASF et al). 2005;42:282-292
— and Doo E. Assessment of liver fibrosis: palpate, poke or pulse? 2005;42:759-761 (Editorial)
Giachetti C (*see* Mosley JW et al). 2005;42:86-92
Gigou M (*see* Guettier C et al). 2005;42:35-43
Ginès P (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C. UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. 2005;42:448-457
Girard H (*see* Guillemette C and Girard H). 2005;42:1463 (Reply)
Glantz A, Marschall HU, Lammert F, Mattsson LÅ. Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid. 2005;42:1399-1405
—, Marschall HU, Mattsson LA. Intrahepatic cholestasis of pregnancy and bile acid levels. 2005;42:738 (Reply)
Go N (*see* Djojosubroto MW et al). 2005;42:1127-1136
Goedert JJ (*see* Hisada M et al). 2005;42:1446-1452
Goedken M (*see* Manautou JE et al). 2005;42:1091-1098
Gold EB (*see* Gershwin ME et al). 2005;42:1194-1202
Goldberg DJ (*see* Hutchinson SJ et al). 2005;42:711-723
Golfieri R (*see* Bolondi L et al). 2005;42:27-34
Gomba S (*see* Sarang Z et al). 2005;42:578-587
Gong Y (*see* Wang G et al). 2005;42:871-879
González-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S, Lang T, Baczkowski A, Geffner M, Gupta S, Laughlin M. Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. 2005;42:1010-1018
Goodman Z (*see* Younossi ZM et al). 2005;42:665-674
Goodman ZD (*see* Lok ASF et al). 2005;42:282-292
Gordon HM (*see* Montagnese S et al). 2005;42:772-781
Gores GJ (*see* Anan A and Gores GJ). 2005;42:527-529 (Editorial)

— (*see* Isomoto H et al). 2005;42:1329-1338
— (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Görg B, Wettstein M, Metzger S, Schliess F, Häussinger D. LPS-induced tyrosine nitration of hepatic glutamine synthetase. 2005;42:499 (Correspondence)
Gorrell MD (*see* Wang XM et al). 2005;42:935-945
Gorreta F (*see* Younossi ZM et al). 2005;42:665-674
Goto T (*see* Kato N et al). 2005;42:846-853
Gralla J (*see* Feranchak AP et al). 2005;42:782-792
Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. Trends in health care resource use for hepatitis C virus infection in the United States. 2005;42:1406-1413
Greenblatt DJ (*see* Girard H et al). 2005;42:448-457
Grenard P (*see* Hézode C et al). 2005;42:63-71
Grey ST (*see* Longo CR et al). 2005;42:156-164
Grigioni WF (*see* Bolondi L et al). 2005;42:27-34
Groothuis GMM (*see* Hofmann AF et al). 2005;42:1391-1398
Grosse-Wilde A (*see* Herzer K et al). 2005;42:183-192
Gruppuso PA (*see* Embree-Ku M and Gruppuso PA). 2005;42:326-334
Gryaznow S (*see* Djojosubroto MW et al). 2005;42:1127-1136
Guettier C, Sebagh M, Buard J, Feneux D, Ortin-Serrano M, Gigou M, Tricottet V, Reynès M, Samuel D, Féray C. Male cell microchimerism in normal and diseased female livers from fetal life to adulthood. 2005;42:35-43
Guicciardi ME (*see* Isomoto H et al). 2005;42:1329-1338
Guillemette C and Girard H. It takes more than one—Is a single UGT polymorphism enough to bother detoxification? 2005;42:1463 (Reply)
Guillemette C (*see* Girard H et al). 2005;42:448-457
Günther S (*see* Hass M et al). 2005;42:93-103
Gupta S (*see* Benten D et al). 2005;42:140-148, 1072-1081
— (*see* Dent P et al). 2005;42:1291-1299
— (*see* González-Peralta RP et al). 2005;42:1010-1018
Gustot T (*see* Moreno C et al). 2005;42:854-862
Gutierrez JA (*see* Schiano TD et al). 2005;42:1420-1428
Gutzeit C (*see* Brandenburg B et al). 2005;42:1300-1309

H

Haas TL (*see* Ganten TM et al). 2005;42:588-597
Haber B (*see* González-Peralta RP et al). 2005;42:1010-1018
Hadziyannis SJ (*see* Papatheodoridis GV et al). 2005;42:121-129
Hagey LR (*see* Hofmann AF et al). 2005;42:1391-1398
Hahn SH (*see* Perri RE et al). 2005;42:974 (Correspondence)
Haida C (*see* Sypsa VA et al). 2005;42:77-85
Halfon P (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Halilbasic E (*see* Wagner M et al). 2005;42:420-430
Halprin A (*see* Everson GT et al). 2005;42:255-262 (Rapid Communication)
Halsall DJ (*see* Zoller H et al). 2005;42:466-472
HALT-C Trial Group (*see* Lok ASF et al). 2005;42:282-292
Hamada K (*see* Kuzumoto Y et al). 2005;42:608-617
Hamann A (*see* Bertolino P et al). 2005;42:1063-1071
Hannoun C (*see* Hass M et al). 2005;42:93-103
Hannun YA (*see* Osawa Y et al). 2005;42:1320-1328
Hao Q (*see* Girard H et al). 2005;42:448-457
Harley CB (*see* Djojosubroto MW et al). 2005;42:1127-1136
Harley HAJ (*see* Helbig KJ et al). 2005;42:702-710
Hashimoto E (*see* Yamauchi K et al). 2005;42:149-155
Hass M, Hannoun C, Kalinina T, Sommer G, Manegold C, Günther S. Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals. 2005;42:93-103
Hatzakis A (*see* Sypsa VA et al). 2005;42:77-85
Häussinger D (*see* Görg B et al). 2005;42:499 (Correspondence)
— (*see* Keitel V et al). 2005;42:978 (Reply)
Haydon G (*see* Forrest E et al). 2005;42:495 (Correspondence)
Hayes P (*see* Forrest E et al). 2005;42:495 (Correspondence)
Heathcote EJ (*see* Feld J and Heathcote EJ). 2005;42:1237-1238 (Reply)
— (*see* Feld JJ et al). 2005;42:53-62
Helbig KJ, Lau DTY, Semendric L, Harley HAJ, Beard MR. Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector. 2005;42:702-710
Heller T and Seeff LB. Viral load as a predictor of progression of chronic hepatitis C? 2005;42:1261-1263 (Editorial)
Heneghan MA and McFarlane IG. Of mice and women: toward a mouse model of autoimmune hepatitis. 2005;42:17-20 (Editorial)
Herkel J (*see* Wiegard C et al). 2005;42:193-199
Herrmann E (*see* Perelson AS et al). 2005;42:749-754 (Concise Review in Mechanisms of Disease)
Herzer K, Ganten TM, Schuulze-Bergkamen H, Grosse-Wilde A, Koschny R, Krammer PH, Walczak H. Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells. 2005;42:183-192
Heuckeroth RO (*see* Wang H et al). 2005;42:1099-1108
Heyninck K (*see* Wullaert A et al). 2005;42:381-389
Hézode C, Roudot-Thoraval F, Nguyen S, Grenard P, Julien B, Zafrani ES, Pawlotsky JM, Dhumeaux D, Lotersztajn S, Mallat A. Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C. 2005;42:63-71
Hezode C (*see* Mallat A et al). 2005;42:976-977 (Reply)
Hildt E (*see* Brandenburg B et al). 2005;42:1300-1309
Hilmer SN, Cogger VC, Fraser R, McLean AJ, Sullivan D, Le Couteur DG. Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat. 2005;42:1349-1354
Hiraga N (*see* Tsuge M et al). 2005;42:1046-1054
Hirano K (*see* Nakayama Y et al). 2005;42:915-924
Hiron M (*see* Coulouarn C et al). 2005;42:946-955
Hisada M, Chatterjee N, Kalaylioglu Z, Battjes RJ, Goedert JJ. Hepatitis C virus load and survival among injection drug users in the United States. 2005;42:1446-1452
Ho C (*see* Zhang T et al). 2005;42:819-827
Ho WZ (*see* Zhang T et al). 2005;42:819-827
Hofmann AF, Zakko SF, Lira M, Clerici C, Hagey LR, Lambert KK, Steinbach JH, Schteingart CD, Olinga P, Groothuis GMM. Novel biotransformation and physiological properties of norursodeoxycholic acid in humans. 2005;42:1391-1398
— (*see* Combes B et al). 2005;42:1184-1193
Hofschneider PH (*see* Brandenburg B et al). 2005;42:1300-1309
Hogaboam CM (*see* Zhou F et al). 2005;42:372-380
Hogg N (*see* Bertolino P et al). 2005;42:1063-1071

Höhler T, Reuss E, Freitag CM, Schneider PM. A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A. 2005;42:72-76
Holz L (*see* Bertolino P et al). 2005;42:1063-1071
Hoofnagle JH. AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff. 2005;42:1246-1247 (2005 AASLD Awardees)
—. Hepatitis B. 2005;42:748 (This Month from the NIH)
—. Milk thistle and chronic liver disease. 2005;42:4 (This Month from the NIH)
— (*see* Zakhari S and Hoofnagle JH). 2005;42:1243 (This Month from the NIH)
Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletecher SP, Steffy KR, Bauman LA, Kerr BM, Averett DR. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. 2005;42:724-731
Horton JD (*see* Beltroy EP et al). 2005;42:886-893
Hoshida Y (*see* Kato N et al). 2005;42:846-853
Housset C (*see* Chignard N et al). 2005;42:549-557
Huang W (*see* Columbano A et al). 2005;42:1118-1126
Hubert-Fouchard I (*see* Calès P et al). 2005;42:1373-1381
Huet PM and Villeneuve JP. Microcirculation of the aging liver: Is getting old like having cirrhosis? 2005;42:1248-1251 (Editorial)
Huitfeldt HS (*see* Rosseland CM et al). 2005;42:200-207
Huo TI, Wu JC, Lee SD. Comparison of staging systems for HCC: one more positive answer or mission impossible? 2005;42:238-239 (Correspondence)
Hutchinson SJ, Bird SM, Goldberg DJ. Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland. 2005;42:711-723
Hylemon PB (*see* Dent P et al). 2005;42:1291-1299
Hynan LS (*see* Larson AM et al). 2005;42:1364-1372

I

Iavarone M (*see* Lampertico P et al). 2005;42:1414-1419
Ichiki Y (*see* Mao TK et al). 2005;42:802-808
Ikeda N (*see* Kuzumoto Y et al). 2005;42:608-617
Ikeda R (*see* Yamamoto Y et al). 2005;42:558-567
Imamura M (*see* Tsuge M et al). 2005;42:1046-1054
Inagaki Y (*see* Svegliati-Baroni G et al). 2005;42:343-352
Inchauspé G (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Iovanna JL (*see* Taïeb D et al). 2005;42:176-182
Ip WK (*see* Chong WP et al). 2005;42:1037-1045
Ishibashi H (*see* Mao TK et al). 2005;42:802-808
Ishida K (*see* Yamauchi K et al). 2005;42:149-155
Ishii K (*see* Kato N et al). 2005;42:846-853
Islam A (*see* Nam SW et al). 2005;42:809-818
Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA, Gores GJ. Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells. 2005;42:1329-1338
Ittrich C (*see* Stahl S et al). 2005;42:353-361
Iwao E (*see* Tsuge M et al). 2005;42:1046-1054

J

Jackson C (*see* Montagnese S et al). 2005;42:772-781
Jaeschke H, Mullen K, Moradpour D. Hepatology *Elsewhere*. 2005;42:216-221, 490-494, 732-735, 956-961, 1203-1207, 1453-1459
Jan YY (*see* Yeh TS et al). 2005;42:657-664
Jansen P (*see* Balistreri WF et al). 2005;42:222-235 (Special Article)
Janssen HLA and Lau GKK. Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs. 2005;42:1459 (Correspondence)
Jethwa N (*see* Montagnese S et al). 2005;42:772-781
Jhaveri RR (*see* Grant WC et al). 2005;42:1406-1413
Ji G (*see* Kato N et al). 2005;42:846-853
Jiménez W (*see* Fernández J et al). 2005;42:627-634
— (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Jin HT (*see* Youn YW et al). 2005;42:1429-1436
Jobst J (*see* Stahl S et al). 2005;42:353-361
Jonas MM (*see* González-Peralta RP et al). 2005;42:1010-1018
Jones DEJ. Fat is an immuno-regulatory issue. 2005;42:755-758 (Editorial)
Jonsson RR (*see* Powell EE et al). 2005;42:5-13 (Perspectives in Clinical Hepatology)
Jorgensen RA (*see* Zein CO et al). 2005;42:762-771
Joseph B (*see* Benten D et al). 2005;42:1072-1081
Julien B (*see* Hézode C et al). 2005;42:63-71
Juran BD and Lazaridis KN. Is the FXR the fix for cholesterol gallstone disease? 2005;42:218-221 (Hepatology *Elsewhere*)

K

Kaiser S (*see* Stahl S et al). 2005;42:353-361
Kakar S (*see* Monto A et al). 2005;42:310-316
Kalaylioglu Z (*see* Hisada M et al). 2005;42:1446-1452
Kalinichenko VV (*see* Costa RH et al). 2005;42:1004-1008 (Editorial)
Kalinina T (*see* Hass M et al). 2005;42:93-103
Kallen KJ (*see* Wiegard C et al). 2005;42:193-199
Kamath PS (*see* Dunn W et al). 2005;42:495-496 (Reply)
— (*see* Perri RE et al). 2005;42:974 (Correspondence)
Kanehiro H (*see* Kuzumoto Y et al). 2005;42:608-617
Kann M (*see* Rösler C et al). 2005;42:301-309
Kaplan MM (*see* Gershwin ME et al). 2005;42:1194-1202
Kaplowitz N. Hepatology Highlights. 2005;42:247-248, 985-986
Kardon T (*see* Sarang Z et al). 2005;42:578-587
Karpen SJ. Exercising the nuclear option to treat cholestasis: CAR and PXR ligands. 2005;42:266-269 (Editorial)
— (*see* Balistreri WF et al). 2005;42:222-235 (Special Article)
Kashizuka H (*see* Kuzumoto Y et al). 2005;42:608-617
Kato N, Ji G, Wang Y, Baba M, Hoshida Y, Otsuka M, Taniguchi H, Moriyama M, Dharel N, Goto T, Shao RX, Matsuura T, Ishii K, Shiina S, Kawabe T, Muramatsu M, Omata M. Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C. 2005;42:846-853
Kato T (*see* Yamamoto Y et al). 2005;42:558-567
Katz SC, Pillarisetty VG, Bleier JI, Kingham TP, Chaudhry UI, Shah AB, DeMatteo RP. Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors. 2005;42:293-300
Kauf TL (*see* Grant WC et al). 2005;42:1406-1413
Kawabe T (*see* Kato N et al). 2005;42:846-853

Keach JC (*see* Zein CO et al). 2005;42:762-771
Keitel V, Burdelski M, Keppler D, Häussinger D, Kubitz R. Vagaries of impaired transporter function in PFIC 2 and 3. 2005;42:978 (Reply)
Kelly DA (*see* González-Peralta RP et al). 2005;42:1010-1018
Kelly DP (*see* You M et al). 2005;42:568-577
Kelly S (*see* Yu XX et al). 2005;42:362-371
Keppler D (*see* Keitel V et al). 2005;42:978 (Reply)
Kerr BM (*see* Horsmans Y et al). 2005;42:724-731
Kersting N (*see* Spangenberg HC et al). 2005;42:828-837
Kerzer K (*see* Ganten TM et al). 2005;42:588-597
Khaykis I (*see* Shim M et al). 2005;42:688-695
Kim CM (*see* Youn YW et al). 2005;42:1429-1436
Kim SY (*see* Nam SW et al). 2005;42:809-818
Kim WR (*see* Dunn W et al). 2005;42:495-496 (Reply)
King R (*see* Feranchak AP et al). 2005;42:782-792
Kingham TP (*see* Katz SC et al). 2005;42:293-300
Kinoshita K (*see* Yamamoto Y et al). 2005;42:558-567
Kitis G (*see* Papatheodoridis GV et al). 2005;42:121-129
Klein AS (*see* Nagakawa Y et al). 2005;42:208-215
Klein C (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Klugewitz K (*see* Bertolino P et al). 2005;42:1063-1071
Kobayashi S (*see* Isomoto H et al). 2005;42:1329-1338
Köck J (*see* Baumert TF et al). 2005;42:21-23 (Editorial)
— (*see* Rösler C et al). 2005;42:301-309
Köhle C (*see* Stahl S et al). 2005;42:353-361
Komatsu T (*see* Yamauchi K et al). 2005;42:149-155
Konaté A (*see* Calès P et al). 2005;42:1373-1381
Koop DR (*see* Deng Q et al). 2005;42:905-914
Kopper L (*see* Paku S et al). 2005;42:863-870
Koschny R (*see* Ganten TM et al). 2005;42:588-597
— (*see* Herzer K et al). 2005;42:183-192
Kosyk O (*see* Powell CL et al). 2005;42:1137-1147
Kowdley KV (*see* Campbell MS et al). 2005;42:635-640
— (*see* Combes B et al). 2005;42:1184-1193
Krammer PH (*see* Herzer K et al). 2005;42:183-192
Kranenburg O (*see* van der Bilt JDW et al). 2005;42:165-175
Kreipe H (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Kren BT (*see* Solá S et al). 2005;42:925-934
Kubicka S (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Kubitz R (*see* Keitel V et al). 2005;42:978 (Reply)
Kubo A (*see* Kuzumoto Y et al). 2005;42:608-617
Kugelmas M (*see* Everson GT et al). 2005;42:255-262 (Rapid Communication)
Kuiken C (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Kuipers F (*see* Geuken E et al). 2005;42:1166-1174
Kumaran V (*see* Benten D et al). 2005;42:140-148, 1072-1081
Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. 2005;42:650-656
Kunne C (*see* Manautou JE et al). 2005;42:1091-1098
Kuzumoto Y, Sho M, Ikeda N, Hamada K, Mizuno T, Akashi S, Tsurui Y, Kashizuka H, Nomi T, Kubo A, Kanehiro H, Nakajima Y. Significance and therapeutic potential of prostaglandin E_2 receptor in hepatic ischemia/reperfusion injury in mice. 2005;42:608-617

L

Laffi G (*see* Aleffi S et al). 2005;42:1339-1348
Lagoa CE, Vodovotz Y, Stolz DB, Lhuillier F, McCloskey C, Gallo D, Yang R, Ustinova E, Fink MP, Billiar TR, Mars WM. The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock. 2005;42:390-399
Lai CL (*see* Chong WP et al). 2005;42:1037-1045
Lai JP (*see* Zhang T et al). 2005;42:819-827
Lake JR (*see* Combes B et al). 2005;42:1184-1193
Lalani E (*see* Larson AM et al). 2005;42:1364-1372
Laleman W, Omasta A, Van de Casteele M, Zeegers M, Vander Elst I, Van Landeghem L, Severi T, van Pelt J, Roskams T, Fevery J, Nevens F. A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis. 2005;42:1382-1390
Lambert KK (*see* Hofmann AF et al). 2005;42:1391-1398
Lambris JD (*see* DeAngelis RA et al). 2005;42:1148-1157
Lammert F (*see* Glantz A et al). 2005;42:1399-1405
Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. 2005;42:1414-1419
Lang T (*see* González-Peralta RP et al). 2005;42:1010-1018
Langer DA and Shah VH. A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension. 2005;42:1255-1257 (Editorial)
Länger P (*see* Seidel N et al). 2005;42:113-120
Langner C (*see* Wagner M et al). 2005;42:420-430
Lapierre P (*see* Marceau G et al). 2005;42:675-682
Larson AM, Polson J, Fontana RJ, Davern TJ, Lalani E, Hynan LS, Reisch JS, Schiødt FV, Ostapowicz G, Shakil AO, Lee WM, Acute Liver Failure Study Group. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. 2005;42:1364-1372
Lau CK (*see* Tsui TY et al). 2005;42:335-342
Lau DTY, Luxon BA, Xiao SY, Beard MR, Lemon SM. Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. 2005;42:273-281
— (*see* Helbig KJ et al). 2005;42:702-710
Lau GKK (*see* Janssen HLA and Lau GKK). 2005;42:1459 (Correspondence)
Lau YL (*see* Chong WP et al). 2005;42:1037-1045
Lauer GM (*see* Cox AL et al). 2005;42:104-112
Laughlin M (*see* González-Peralta RP et al). 2005;42:1010-1018
Lauletta G (*see* Sansanno D et al). 2005;42:1019-1027
Lauwers GY (*see* Pawlik TM et al). 2005;42:738-739 (Correspondence)
Lavillette D (*see* Youn YW et al). 2005;42:1429-1436
Lavine JE (*see* Schwimmer JB et al). 2005;42:641-649
Lazaridis KN (*see* Juran BD and Lazaridis KN). 2005;42:218-221 (Hepatology *Elsewhere*)
Lazenby AJ (*see* Abrams GA et al). 2005;42:1461 (Reply)
— (*see* Kunde SS et al). 2005;42:650-656
Le Couteur DG (*see* Hilmer SN et al). 2005;42:1349-1354
Le Moine O (*see* Moreno C et al). 2005;42:854-862

Le T (*see* Zhou F et al). 2005;42:372-380
Ledda-Columbano GM (*see* Columbano A et al). 2005;42:1118-1126
Lee CG (*see* Youn YW et al). 2005;42: 1429-1436
Lee DH (*see* Youn YW et al). 2005;42: 1429-1436
Lee JY (*see* Ballatori N et al). 2005;42: 1270-1279
— (*see* Nam SW et al). 2005;42:809-818
Lee SD (*see* Huo TI et al). 2005;42:238-239 (Correspondence)
Lee SH (*see* Nam SW et al). 2005;42:809-818
Lee SS. AASLD 2005 Distinguished Achievement Award to Dr. Jenny Heathcote. 2005;42:1244-1245 (2005 AASLD Awardees)
— (*see* Liu H and Lee SS). 2005;42:1203-1205 (Hepatology *Elsewhere*)
Lee WM (*see* Larson AM et al). 2005;42: 1364-1372
— (*see* Lok ASF et al). 2005;42:282-292
Lefebvre G (*see* Coulouarn C et al). 2005; 42:946-955
Lemon SM (*see* Lau DTY et al). 2005;42: 273-281
Lentsch AB. Activation and function of hepatocyte NF-κB in postischemic liver injury. 2005;42:216-218 (Hepatology *Elsewhere*)
Lenz K. Hepatorenal syndrome—Is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? 2005;42: 263-265 (Editorial)
Leone TC (*see* You M et al). 2005;42:568-577
Leoni S (*see* Bolondi L et al). 2005;42:27-34
Letellier F (*see* Coulouarn C et al). 2005; 42:946-955
Lettéron P (*see* Robin MA et al). 2005;42: 1280-1290
Leuvenink HGD (*see* Geuken E et al). 2005;42:1166-1174
Lhuillier F (*see* Lagoa CE et al). 2005;42: 390-399
Li JQ (*see* Zeng MD et al). 2005;42:1437-1445
Li N (*see* Ballatori N et al). 2005;42:1270-1279
Li Y (*see* Zhang T et al). 2005;42:819-827
Li Z, Soloski MJ, Diehl AM. Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease. 2005;42:880-885
Lian ZX (*see* Mao TK et al). 2005;42:802-808
Libbrecht L, Maleux G, Verslype C, Nevens F, Roskams T. Influence of TIPS on development of hepatocellular carcinoma in cirrhosis. 2005;42:236 (Correspondence)
Libert C (*see* Wullaert A et al). 2005;42: 381-389
Libra M (*see* Sansanno D et al). 2005;42: 1019-1027
Lieu HT, Batteux F, Simion MT, Cortes A, Nicco C, Zavala F, Pauloin A, Tralhao JG, Soubrane O, Weill B, Bréchot C, Christa L. HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice. 2005;42:618-626
Lin RT (*see* Zhang T et al). 2005;42:819-827
Lindor KD (*see* Gershwin ME et al). 2005; 42:1194-1202
— (*see* Zein CO et al). 2005;42:762-771
Lindsay KL (*see* Combes B et al). 2005;42: 1184-1193
— (*see* Lok ASF et al). 2005;42:282-292
Lira M (*see* Hofmann AF et al). 2005;42: 1391-1398
Liu ET (*see* Nam SW et al). 2005;42:809-818
Liu H and Lee SS. What happens to cirrhotic cardiomyopathy after liver transplantation? 2005;42:1203-1205 (Hepatology *Elsewhere*)
Liu NJ (*see* Yeh TS et al). 2005;42:657-664
Liu S (*see* Ma H et al). 2005;42:1355-1363
Liu Y (*see* Ma H et al). 2005;42:1355-1363
Li-Weber M (*see* Ganten TM et al). 2005; 42:588-597
Lledó L (*see* Muñoz L et al). 2005;42:411-419
Lo Iacono O (*see* Ripoll C et al). 2005;42: 793-801
Lobenhofer EK (*see* Powell CL et al). 2005; 42:1137-1147
Locker J (*see* Columbano A et al). 2005;42: 1118-1126
Lohse AW (*see* Wiegard C et al). 2005;42: 193-199
Lok AS (*see* Marrero JA et al). 2005;42: 739-740 (Reply)
Lok ASF, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, Lee WM, Morgan TR, Dienstag JL, Morishima C, HALT-C Trial Group. Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. 2005;42:282-292
Long PM (*see* Nam SW et al). 2005;42: 809-818
Longo CR, Patel VI, Shrikhande GV, Scali ST, Csizmadia E, Daniel S, Sun DW, Grey ST, Arvelo MB, Ferran C. A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism. 2005;42:156-164
López-Cabrera M (*see* Salcedo X et al). 2005;42:696-701
Lotersztajn S (*see* Hézode C et al). 2005;42: 63-71
— (*see* Mallat A et al). 2005;42:976-977 (Reply)
Louis H (*see* Moreno C et al). 2005;42: 854-862
Lu LG (*see* Zeng MD et al). 2005;42:1437-1445
Lu Y (*see* Wang X et al). 2005;42:400-410
Luketic VA (*see* Combes B et al). 2005;42: 1184-1193
Lunel F (*see* Calès P et al). 2005;42:1373-1381
Lunghi G (*see* Lampertico P et al). 2005; 42:1414-1419
Lupberger J (*see* Brandenburg B et al). 2005;42:1300-1309
Lurie Y (*see* González-Peralta RP et al). 2005;42:1010-1018
Luxon BA (*see* Lau DTY et al). 2005;42: 273-281

M

Ma H, Liu Y, Liu S, Xu R, Zheng D. Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice. 2005;42:1355-1363
Ma J (*see* Tsui TY et al). 2005;42:335-342
Ma Y (*see* Bogdanos DP et al). 2005;42: 458-465
Macías J, Mira JA, Vergara S, Pineda JA. Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C. 2005;42:498 (Correspondence)
Madejczyk MS (*see* Ballatori N et al). 2005; 42:1270-1279
Maertens G (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Magalotti D (*see* Villanova N et al). 2005; 42:473-480
Magder LS (*see* Mohamed MK et al). 2005; 42:683-687
Maisonneuve C (*see* Robin MA et al). 2005;42:1280-1290
Makar GA (*see* Campbell MS and Makar GA). 2005;42:237 (Correspondence)
Malicet C (*see* Taïeb D et al). 2005;42:176-182
Malim MH (*see* Rösler C et al). 2005;42: 301-309
Mallat A, Hezode C, Lotersztajn S. Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. 2005;42:976-977 (Reply)
— (*see* Hézode C et al). 2005;42:63-71
Manautou JE, de Waart DR, Kunne C, Zelcer N, Goedken M, Borst P, Elferink RO. Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene. 2005; 42:1091-1098
Manegold C (*see* Hass M et al). 2005;42: 93-103
Manenti E (*see* Lampertico P et al). 2005; 42:1414-1419
Manesis E (*see* Papatheodoridis GV et al). 2005;42:121-129

Manns MP (*see* Djojosubroto MW et al). 2005;42:1127-1136
— (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
— (*see* Seidel N et al). 2005;42:113-120
— (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Manolakopoulos S (*see* Papatheodoridis GV et al). 2005;42:121-129
Mao TK, Lian ZX, Selmi C, Ichiki Y, Ashwood P, Ansari AA, Coppel RL, Shimoda S, Ishibashi H, Gershwin ME. Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis. 2005;42:802-808
Mao YM (*see* Zeng MD et al). 2005;42:1437-1445
Marceau G, Lapierre P, Béland K, Soudeyns H, Alvarez F. LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? 2005;42:675-682
Marchesini G (*see* Bedogni G et al). 2005;42:44-52
— (*see* Bugianesi E et al). 2005;42:987-1000 (Concise Review in Mechanisms of Disease)
— (*see* Villanova N et al). 2005;42:473-480
Marcus VA (*see* Feld JJ et al). 2005;42:53-62
Markiewski MM (*see* DeAngelis RA et al). 2005;42:1148-1157
Markin RS (*see* Combes B et al). 2005;42:1184-1193
Marpeau L (*see* Sentilhes L et al). 2005;42:737-738 (Correspondence)
Marra F (*see* Aleffi S et al). 2005;42:1339-1348
Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Lok AS. Staging of hepatocellular carcinoma. 2005;42:739-740 (Reply)
Mars WM (*see* Lagoa CE et al). 2005;42:390-399
Marschall HU (*see* Glantz A et al). 2005;42:738 (Reply), 1399-1405
— (*see* Wagner M et al). 2005;42:420-430
Martin S (*see* González-Peralta RP et al). 2005;42:1010-1018
Martinez EJ (*see* Combes B et al). 2005;42:1184-1193
Martín-Vilchez S (*see* Salcedo X et al). 2005;42:696-701
Marx-Stoelting P (*see* Stahl S et al). 2005;42:353-361
Masini A (*see* Riggio O et al). 2005;42:1158-1165
Masutti F (*see* Bedogni G et al). 2005;42:44-52
Matilla A (*see* Ripoll C et al). 2005;42:793-801
Matsubara K (*see* Yamamoto Y et al). 2005;42:558-567
Matsuura T (*see* Kato N et al). 2005;42:846-853
Mattsson LÅ (*see* Glantz A et al). 2005;42:738 (Reply), 1399-1405
Maxcey C (*see* Zhang T et al). 2005;42:819-827
Mayo MJ (*see* Combes B et al). 2005;42:1184-1193
McCashland T (*see* Campbell MS et al). 2005;42:635-640
McCashland TM (*see* Combes B et al). 2005;42:1184-1193
McCaughan GW (*see* Bertolino P et al). 2005;42:1063-1071
— (*see* Wang XM et al). 2005;42:935-945
McCloskey C (*see* Lagoa CE et al). 2005;42:390-399
McCullough AJ (*see* Bugianesi E et al). 2005;42:987-1000 (Concise Review in Mechanisms of Disease)
McFarlane I (*see* Zoller H et al). 2005;42:466-472
McFarlane IG (*see* Heneghan MA and McFarlane IG). 2005;42:17-20 (Editorial)
McHutchison JG (*see* Grant WC et al). 2005;42:1406-1413
McKay R (*see* Yu XX et al). 2005;42:362-371
McKinney D (*see* Spangenberg HC et al). 2005;42:828-837
McLean AJ (*see* Hilmer SN et al). 2005;42:1349-1354
McPherson D. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. 2005;42:975 (Reply)
McPherson DD. Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between? 2005;42:270-272 (Editorial)
Mecarelli O (*see* Riggio O et al). 2005;42:1158-1165
Medhat A (*see* Mohamed MK et al). 2005;42:683-687
Medina J (*see* Salcedo X et al). 2005;42:696-701
Mehta S, Thomas D, Sulkowski M. Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C. 2005;42:498-499 (Reply)
Melino G (*see* Sarang Z et al). 2005;42:578-587
Menegazzi M (*see* Columbano A et al). 2005;42:1118-1126
Mergey M (*see* Chignard N et al). 2005;42:549-557
Merli M (*see* Riggio O et al). 2005;42:1158-1165
Metzger S (*see* Görg B et al). 2005;42:499 (Correspondence)
Michalak S (*see* Calès P et al). 2005;42:1373-1381
Micol F (*see* Perelson AS et al). 2005;42:749-754 (Concise Review in Mechanisms of Disease)
Mieli-Vergani G (*see* González-Peralta RP et al). 2005;42:1010-1018
Miglioli L (*see* Bedogni G et al). 2005;42:44-52
Mikhail NN (*see* Mohamed MK et al). 2005;42:683-687
Milani S (*see* Aleffi S et al). 2005;42:1339-1348
Milicua JM (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Miller LD (*see* Nam SW et al). 2005;42:809-818
Mills AS (*see* Combes B et al). 2005;42:1184-1193
Mimidis K (*see* Sypsa VA et al). 2005;42:77-85
Minemura M (*see* Nakayama Y et al). 2005;42:915-924
Minisini R (*see* Colletta C et al). 2005;42:838-845
Minuk G (*see* Wang G et al). 2005;42:871-879
Mira JA (*see* Macías J et al). 2005;42:498 (Correspondence)
Mitchell C (*see* Dent P et al). 2005;42:1291-1299
Mizokami M (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Mizuno T (*see* Kuzumoto Y et al). 2005;42:608-617
Mohamed MK, Abdel-Hamid M, Mikhail NN, Abdel-Aziz F, Medhat A, Magder LS, Fix AD, Strickland GT. Intrafamilial transmission of hepatitis C in Egypt. 2005;42:683-687
Molinero LM (*see* Ripoll C et al). 2005;42:793-801
Molleston J (*see* González-Peralta RP et al). 2005;42:1010-1018
Molleston JP. The histopathology of pediatric nonalcoholic fatty liver disease. 2005;42:536-538 (Editorial)
Molnár P (*see* Sarang Z et al). 2005;42:578-587
Monescillo A (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Monia BP (*see* Yu XX et al). 2005;42:362-371
Monserrat J (*see* Muñoz L et al). 2005;42:411-419
Montagnese S, Gordon HM, Jackson C, Smith J, Tognella P, Jethwa N, Sherratt RM, Morgan MY. Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment. 2005;42:772-781
Montalto P (*see* Bogdanos DP et al). 2005;42:458-465
Monteagudo J (*see* Fernández J et al). 2005;42:627-634
Montgomery RA (*see* Nagakawa Y et al). 2005;42:208-215
Monto A, Dove LM, Bostrom A, Kakar S, Tien PC, Wright TL. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and

significance compared with hepatitis C monoinfection. 2005;42:310-316
Montrone M (*see* Sansanno D et al). 2005; 42:1019-1027
Moore DD (*see* Columbano A et al). 2005; 42:1118-1126
Moradpour D, Brass V, Penin F. Function follows form: the structure of the N-terminal domain of HCV NS5A. 2005;42:732-735 (Hepatology *Elsewhere*)
— (*see* Berke JM and Moradpour D). 2005;42:1264-1269 (Science Frontier)
— (*see* Jaeschke H et al). 2005;42:216-221, 732-735, 956-961, 1203-1207, 1453-1459
Moreira V (*see* Ruiz-del-Arbol L et al). 2005;42:439-447
Moreno C, Gustot T, Nicaise C, Quertinmont E, Nagy N, Parmentier M, Le Moine O, Devière J, Louis H. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. 2005;42: 854-862
Moreno-Otero R (*see* Salcedo X et al). 2005;42:696-701
Morgan MY (*see* Montagnese S et al). 2005;42:772-781
Morgan TR (*see* Lok ASF et al). 2005;42: 282-292
Morishima C (*see* Lok ASF et al). 2005;42: 282-292
Moriyama M (*see* Kato N et al). 2005;42: 846-853
Mosbruger T (*see* Cox AL et al). 2005;42: 104-112
Moscatiello S (*see* Villanova N et al). 2005; 42:473-480
Mosley JW, Operskalski EA, Tobler LH, Andrews WW, Phelps B, Dockter J, Giachetti C, Busch MP. Viral and host factors in early hepatitis C virus infection. 2005;42:86-92
Moulakakis A (*see* Sypsa VA et al). 2005; 42:77-85
Mueller T (*see* Horsmans Y et al). 2005;42: 724-731
Muir AJ (*see* Brady CW and Muir AJ). 2005;42:496-497 (Correspondence)
Mullen K (*see* Jaeschke H et al). 2005;42: 216-221, 490-494, 732-735, 956-961, 1203-1207, 1453-1459
Mullen KD (*see* Ghanta RK and Mullen KD). 2005;42:1206-1207 (Hepatology *Elsewhere*)
Mullerova I (Rigopoulou EI et al). 2005; 42:1028-1036
Muñoz L, Albillos A, Nieto M, Reyes E, Lledó L, Monserrat J, Sanz E, de la Hera A, Alvarez-Mon M. Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis. 2005;42:411-419
Munoz SJ (*see* Combes B et al). 2005;42: 1184-1193
Muntoni MD (*see* Pascale RM et al). 2005; 42:1310-1319
Muramatsu M (*see* Kato N et al). 2005;42: 846-853
Murata S (*see* Yamamoto Y et al). 2005;42: 558-567
Muroni MR (*see* Pascale RM et al). 2005; 42:1310-1319
Murphy DG (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Murray KF (*see* González-Peralta RP et al). 2005;42:1010-1018
Murray SF (*see* Yu XX et al). 2005;42:362-371
Musso G, Gambino R, Durazzo M, Biroli G, Carelloo M, Fagà E, Pacini G, De Michieli F, Rabbione L, Premoli A, Cassader M, Pagano G. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. 2005;42:1175-1183
Myara A (*see* Bellodi-Privato M et al). 2005;42:431-438

N

Nagahara H (*see* Yamauchi K et al). 2005; 42:149-155
Nagakawa Y, Williams GM, Zheng Q, Tsuchida A, Aoki T, Montgomery RA, Klein AS, Sun Z. Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α. 2005;42:208-215
Nagorney DM (*see* Pawlik TM et al). 2005; 42:738-739 (Correspondence)
Nagy N (*see* Moreno C et al). 2005;42: 854-862
Nagy P (*see* Paku S et al). 2005;42:863-870
Nakae D (*see* Powell CL et al). 2005;42: 1137-1147
Nakajima Y (*see* Kuzumoto Y et al). 2005; 42:608-617
Nakanishi T (*see* Yamauchi K et al). 2005; 42:149-155
Nakayama Y, Shimizu Y, Hirano K, Ebata K, Minemura M, Watanbe A, Sugiyama T. CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis. 2005;42:915-924
Nam SW, Park JY, Ramasamy A, Shevade S, Islam A, Long PM, Park CK, Park SE, Kim SY, Lee SH, Park WS, You NJ, Liu ET, Miller LD, Lee JY. Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling. 2005;42:809-818
Naoumov NV (Rigopoulou EI et al). 2005; 42:1028-1036
Narkewicz MR (*see* Feranchak AP et al). 2005;42:782-792
Navasa M (*see* Fernández J et al). 2005;42: 627-634
Nemeth E (*see* Zoller H et al). 2005;42: 466-472
Németh T (*see* Sarang Z et al). 2005;42: 578-587
Neumann AU. Hepatitis B viral kinetics: a dynamic puzzle still to be resolved. 2005;42:249-254 (Perspectives in Clinical Hepatology)
Neumann-Haefelin C (*see* Spangenberg HC et al). 2005;42:828-837
Nevens F (*see* Laleman W et al). 2005;42: 1382-1390
Newbury R (*see* Schwimmer JB et al). 2005;42:641-649
Nguyen S (*see* Hézode C et al). 2005;42: 63-71
Nicaise C (*see* Moreno C et al). 2005;42: 854-862
Nicco C (*see* Lieu HT et al). 2005;42:618-626
Nicolao F (*see* Riggio O et al). 2005;42: 1158-1165
Nierhoff D, Ogawa A, Oertel M, Chen YQ, Shafritz DA. Purification and characterization of mouse fetal liver epithelial cells with high *in vivo* repopulation capacity. 2005;42:130-139
Nieto M (*see* Muñoz L et al). 2005;42:411-419
Nievergelt C (*see* Schwimmer JB et al). 2005;42:641-649
Nijkamp MW (*see* van der Bilt JDW et al). 2005;42:165-175
Noguchi C (*see* Tsuge M et al). 2005;42: 1046-1054
Nomi T (*see* Kuzumoto Y et al). 2005;42: 608-617
Novo E (*see* Aleffi S et al). 2005;42:1339-1348
Núñez O (*see* Bañares R and Núñez O). 2005;42:236-237 (Reply)
— (*see* Ripoll C et al). 2005;42:793-801

O

Oberti F (*see* Calès P et al). 2005;42:1373-1381
Ochi H (*see* Tsuge M et al). 2005;42:1046-1054
Ochiya T (*see* Yamamoto Y et al). 2005;42: 558-567
Oertel M (*see* Nierhoff D et al). 2005;42: 130-139
Oga H (*see* Tsuge M et al). 2005;42:1046-1054
Ogawa A (*see* Nierhoff D et al). 2005;42: 130-139
O'Grady JG. Broadening the view of acetaminophen hepatotoxicity. 2005; 42:1252-1254 (Editorial)
Okamoto H (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Okamoto M (*see* Bogdanos DP et al). 2005;42:458-465
Oksvold MP (*see* Rosseland CM et al). 2005;42:200-207

Olinga P (*see* Hofmann AF et al). 2005;42:1391-1398
Olsson R (*see* Björnsson E and Olsson R). 2005;42:481-489
Omasta A (*see* Laleman W et al). 2005;42:1382-1390
Omata M (*see* Kato N et al). 2005;42:846-853
Ong JP (*see* Younossi ZM et al). 2005;42:665-674
Operskalski EA (*see* Mosley JW et al). 2005;42:86-92
Ortin-Serrano M (*see* Guettier C et al). 2005;42:35-43
Osawa Y, Hannun YA, Proia RL, Brenner DA. Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver. 2005;42:1320-1328
Osna NA, Clemens DL, Donoue TM Jr. Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells. 2005;42:1109-1117
Ostapowicz G (*see* Larson AM et al). 2005;42:1364-1372
Ostrow JD and Tiribelli C. Vagaries of impaired transporter function in PFIC 2 and 3. 2005;42:977-978 (Correspondence)
Østvold AC (*see* Rosseland CM et al). 2005;42:200-207
Otsuka M (*see* Kato N et al). 2005;42:846-853
Oxley D (*see* Zoller H et al). 2005;42:466-472

P

Pacini G (*see* Musso G et al). 2005;42:1175-1183
Pagano G (*see* Musso G et al). 2005;42:1175-1183
Paku S, Dezs[font"MS Reference 1"]õ[/font"MS Reference 1"] K, Kopper L, Nagy P. Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver. 2005;42:863-870
Palestro CJ (*see* Benten D et al). 2005;42:140-148
Pandey SK (*see* Yu XX et al). 2005;42:362-371
Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. 2005;42:121-129
Papeleu P (*see* Wullaert A et al). 2005;42:381-389
Paradis V (*see* Robin MA et al). 2005;42:1280-1290
Pardoll D (*see* Cox AL et al). 2005;42:104-112
Park CK (*see* Nam SW et al). 2005;42:809-818
Park J (*see* Shim M et al). 2005;42:688-695
Park JY (*see* Nam SW et al). 2005;42:809-818
Park SE (*see* Nam SW et al). 2005;42:809-818
Park SH (*see* Youn YW et al). 2005;42:1429-1436
Park WS (*see* Nam SW et al). 2005;42:809-818
Parker JS (*see* Powell CL et al). 2005;42:1137-1147
Parmentier M (*see* Moreno C et al). 2005;42:854-862
Parola M (*see* Aleffi S et al). 2005;42:1339-1348
Pascale RM, Simile MM, Calvisi DF, Frau M, Muroni MR, Seddaiu MA, Daino L, Muntoni MD, De Miglio MR, Thorgeirsson SS, Feo F. Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in rat liver carcinogenesis and human liver cancer. 2005;42:1310-1319
Patch D (*see* Senzolo M et al). 2005;42:240-241 (Correspondence)
Patel VI (*see* Longo CR et al). 2005;42:156-164
Paul A (*see* Chignard N et al). 2005;42:549-557
Pauloin A (*see* Lieu HT et al). 2005;42:618-626
Paulsen RE (*see* Rosseland CM et al). 2005;42:200-207
Pawlik TM, Abdalla EK, Thomas M, Roh MS, Lauwers GY, Ribero D, Poon RT, Belghiti J, Nagorney DM, Vauthey JN. Staging of hepatocellular carcinoma. 2005;42:738-739 (Correspondence)
Pawlotsky JM (*see* Hézode C et al). 2005;42:63-71
— (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Pearce LL (*see* Chen T et al). 2005;42:598-607
Pediconi F (*see* Riggio O et al). 2005;42:1158-1165
Peeters PMJG (*see* Geuken E et al). 2005;42:1166-1174
Penin F (*see* Moradpour D et al). 2005;42:732-735 (Hepatology *Elsewhere*)
— (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Perelson AS, Herrmann E, Micol F, Zeuzem S. New kinetic models for the hepatitis C virus. 2005;42:749-754 (Concise Review in Mechanisms of Disease)
Perlmutter DH (*see* Rudnick DA and Perlmutter DH). 2005;42:514-521 (Concise Review in Mechanisms of Disease)
Perri RE, Hahn SH, Ferber MJ, Kamath PS. Wilson disease—Keeping the bar for diagnosis raised. 2005;42:974 (Correspondence)
Pessayre D (*see* Robin MA et al). 2005;42:1280-1290
Peters MG (*see* Combes B et al). 2005;42:1184-1193
Petersen J (*see* Dandri M and Petersen J). 2005;42:1453-1455 (Hepatology *Elsewhere*)
Peterson J (*see* Chen T et al). 2005;42:598-607
Petrai I (*see* Aleffi S et al). 2005;42:1339-1348
Pfahler W (*see* Youn YW et al). 2005;42:1429-1436
Phelps B (*see* Mosley JW et al). 2005;42:86-92
Pibiri M (*see* Columbano A et al). 2005;42:1118-1126
Pichard V (*see* Bellodi-Privato M et al). 2005;42:431-438
Pillarisetty VG (*see* Katz SC et al). 2005;42:293-300
Pineda JA and García-García JA. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. 2005;42:497 (Reply)
— (*see* Macías J et al). 2005;42:498 (Correspondence)
Pinzani M (*see* Aleffi S et al). 2005;42:1339-1348
Pirisi M (*see* Colletta C et al). 2005;42:838-845
Piscaglia F (*see* Bolondi L et al). 2005;42:27-34
Plentz RR, Schlegelberger B, Flemming P, Gebel M, Kreipe H, Manns MP, Rudolph KL, Wilkens L. Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma. 2005;42:522-526 (Rapid Communication)
Poirel O (*see* Robin MA et al). 2005;42:1280-1290
Polson J (*see* Larson AM et al). 2005;42:1364-1372
Poon RT (*see* Pawlik TM et al). 2005;42:738-739 (Correspondence)
Poon TP (*see* Chong WP et al). 2005;42:1037-1045
Popov Y (*see* Benten D et al). 2005;42:1072-1081
Porte RJ (*see* Geuken E et al). 2005;42:1166-1174
Powell CL, Kosyk O, Bradford BU, Parker JS, Lobenhofer EK, Denda A, Uematsu F, Nakae D, Rusyn I. Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury. 2005;42:1137-1147
Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver

diseases. 2005;42:5-13 (Perspectives in Clinical Hepatology)
Prati D, Colli A, Conte D, Colombo M. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. 2005;42:1460-1461 (Correspondence)
Premoli A (*see* Musso G et al). 2005;42: 1175-1183
Prince AM (*see* Youn YW et al). 2005;42: 1429-1436
Proia RL (*see* Osawa Y et al). 2005;42: 1320-1328
Purcell RH (*see* Schofield DJ et al). 2005; 42:1055-1062

Q

Qiu DK (*see* Zeng MD et al). 2005;42: 1437-1445
Quertinmont E (*see* Moreno C et al). 2005; 42:854-862
Quinn G (*see* Yamamoto Y et al). 2005;42: 558-567

R

Rabbione L (*see* Musso G et al). 2005;42: 1175-1183
Ramalho RM (*see* Solá S et al). 2005;42: 925-934
Ramasamy A (*see* Nam SW et al). 2005;42: 809-818
Ramilli S (*see* Villanova N et al). 2005;42: 473-480
Ramirez F (*see* Svegliati-Baroni G et al). 2005;42:343-352
Ramirez RO (*see* Feranchak AP et al). 2005;42:782-792
Rapetti R (*see* Colletta C et al). 2005;42: 838-845
Rapti I (*see* Papatheodoridis GV et al). 2005;42:121-129
Raptopoulou M (*see* Sypsa VA et al). 2005; 42:77-85
Ray C (*see* Everson GT et al). 2005;42: 255-262 (Rapid Communication)
Ray SC (*see* Cox AL et al). 2005;42:104-112
Reddy KR (*see* Campbell MS et al). 2005; 42:635-640
Redeker A (*see* Verma S and Redeker A). 2005;42:1237 (Correspondence)
Reisch JS (*see* Larson AM et al). 2005;42: 1364-1372
Reuben A. The biliary cycle of Moritz Schiff. 2005;42:500-505 (Landmarks in Hepatology)
—. First do no harm. 2005;42:1464-1470 (Landmarks in Hepatology)
—. You've gotta have heart! 2005;42:979-983 (Landmarks in Hepatology)
Reuss E (*see* Höhler T et al). 2005;42:72-76
Revicki DA. Methodological issues and the measurement of fatigue in primary biliary cirrhosis. 2005;42:24-26 (Editorial)
Reyes E (*see* Muñoz L et al). 2005;42:411-419
Reynès M (*see* Guettier C et al). 2005;42: 35-43
Ribero D (*see* Pawlik TM et al). 2005;42: 738-739 (Correspondence)
Rice CM and You S. Treating hepatitis C: Can you teach old dogs new tricks? 2005;42:1456-1458 (Hepatology *Elsewhere*)
Rice S (Rigopoulou EI et al). 2005;42: 1028-1036
Richardson JA (*see* Beltroy EP et al). 2005; 42:886-893
Ridola L (*see* Riggio O et al). 2005;42: 1158-1165
Riess O (*see* Stahl S et al). 2005;42:353-361
Riggio O, Efrati C, Catalano C, Pediconi F, Mecarelli O, Accornero N, Nicolao F, Angeloni S, Masini A, Ridola L, Attili AF, Merli M. High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study. 2005;42:1158-1165
Rigopoulou EI, Suri D, Chokshi S, Mullerova I, Rice S, Tedder RS, Williams R, Naoumov NV. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. 2005;42: 1028-1036
— (*see* Bogdanos DP et al). 2005;42:458-465
Rincón D (*see* Ripoll C et al). 2005;42: 793-801
Rincon-Sanchez AR (*see* Svegliati-Baroni G et al). 2005;42:343-352
Ripoll C, Bañares R, Rincón D, Catalina MV, Lo Iacono O, Salcedo M, Clemente G, Núñez O, Matilla A, Molinero LM. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era. 2005;42: 793-801
Roberts MS (*see* Wang G et al). 2005;42: 871-879
Robin MA, Demeilliers C, Sutton A, Paradis V, Maisonneuve C, Dubois S, Poirel O, Lettéron P, Pessayre D, Fromenty B. Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice. 2005;42: 1280-1290
Rocchi P (*see* Taïeb D et al). 2005;42:176-182
Rodrigues CMP (*see* Solá S et al). 2005;42: 925-934
Roggendorf M (*see* Spangenberg HC et al). 2005;42:828-837
Roh MS (*see* Pawlik TM et al). 2005;42: 738-739 (Correspondence)
Rojkind M (*see* Svegliati-Baroni G et al). 2005;42:343-352
Roman H (*see* Sentilhes L et al). 2005;42: 737-738 (Correspondence)
Rombouts K (*see* Aleffi S et al). 2005;42: 1339-1348
Roncoroni L (*see* Costi R et al). 2005;42: 736 (Correspondence)
Roos M (*see* Brandenburg B et al). 2005; 42:1300-1309
Roskams T (*see* Laleman W et al). 2005;42: 1382-1390
Rösler C, Köck J, Kann M, Malim MH, Blum HE, Baumert TF, von Weizsäcker F. APOBEC-mediated interference with hepadnavirus production. 2005;42:301-309
Rosoff L Jr (*see* Combes B et al). 2005;42: 1184-1193
Rosseland CM, Wierød L, Oksvold MP, Werner H, Østvold AC, Thoresen GH, Paulsen RE, Huitfeldt HS, Skarpen E. Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes. 2005;42:200-207
Roudot-Thoraval F (*see* Hézode C et al). 2005;42:63-71
Rousselet MC (*see* Calès P et al). 2005;42: 1373-1381
Rubin R (*see* Combes B et al). 2005;42: 1184-1193
Rudnick DA. Trimming the fat from liver regeneration. 2005;42:1001-1003 (Editorial)
— and Perlmutter DH. Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease. 2005;42:514-521 (Concise Review in Mechanisms of Disease)
Rudolph KL (*see* Djojosubroto MW et al). 2005;42:1127-1136
— (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Ginès P, Moreira V, Milicua JM, Jiménez W, Arroyo V. Circulatory function and hepatorenal syndrome in cirrhosis. 2005;42:439-447
Rusyn I (*see* Powell CL et al). 2005;42: 1137-1147

S

Sablon E (*see* Simmonds P et al). 2005;42: 962-973 (Special Article)
Saccomanno S (*see* Svegliati-Baroni G et al). 2005;42:343-352
Salcedo M (*see* Ripoll C et al). 2005;42: 793-801
Salcedo X, Medina J, Sanz-Cameno P, García-Buey L, Martín-Vilchez S, Borque MJ, López-Cabrera M,

Moreno-Otero R. The potential of angiogenesis soluble markers in chronic hepatitis C. 2005;42:696-701
Salier JP (*see* Coulouarn C et al). 2005;42:946-955
Samuel D (*see* Guettier C et al). 2005;42:35-43
Sansanno D, Tucci FA, De Re V, Lauletta G, Montrone M, Libra M, Drammacco F. HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. 2005;42:1019-1027
Sanyal AJ (*see* Campbell MS et al). 2005;42:635-640
Sanz E (*see* Muñoz L et al). 2005;42:411-419
Sanz-Cameno P (*see* Salcedo X et al). 2005;42:696-701
Sarang Z, Molnár P, Németh T, Gomba S, Kardon T, Melino G, Cotecchia S, Fésüs L, Szondy Z. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. 2005;42:578-587
Sarli L (*see* Costi R et al). 2005;42:736 (Correspondence)
Sauer IM (*see* Brandenburg B et al). 2005;42:1300-1309
Scali ST (*see* Longo CR et al). 2005;42:156-164
Schaetzlein S (*see* Djojosubroto MW et al). 2005;42:1127-1136
Schattenberg J (*see* Benten D et al). 2005;42:1072-1081
Schiano TD, Gutierrez JA, Walewski JL, Fiel MI, Cheng B, Bodenheimer H Jr, Thung SN, Chung RT, Schwartz ME, Bodian C, Branch AD. Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors. 2005;42:1420-1428
Schiødt FV (*see* Larson AM et al). 2005;42:1364-1372
Schlauch K (*see* Younossi ZM et al). 2005;42:665-674
Schlegelberger B (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Schliess F (*see* Görg B et al). 2005;42:499 (Correspondence)
Schlitt HJ (*see* Tsui TY et al). 2005;42:335-342
Schmitt E (*see* Wiegard C et al). 2005;42:193-199
Schneider PM (*see* Höhler T et al). 2005;42:72-76
Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, Emerson SU, Cosset EL, Purcell RH. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and posses neutralizing activity. 2005;42:1055-1062
Schölmerich J (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Schork NJ (*see* Schwimmer JB et al). 2005;42:641-649
Schott E (*see* Horsmans Y et al). 2005;42:724-731
Schotte P (*see* Wullaert A et al). 2005;42:381-389
Schrage A (*see* Bertolino P et al). 2005;42:1063-1071
Schteingart CD (*see* Hofmann AF et al). 2005;42:1391-1398
Schulman KA (*see* Grant WC et al). 2005;42:1406-1413
Schulze-Osthoff K (*see* Seidel N et al). 2005;42:113-120
Schuppan D (*see* Benten D et al). 2005;42:1072-1081
Schuulze-Bergkamen H (*see* Herzer K et al). 2005;42:183-192
Schwabe RF. Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors. 2005;42:959-961 (Hepatology *Elsewhere*)
Schwabe RF and Siegmund SV. Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C. 2005;42:975-976 (Correspondence)
Schwartlander R (*see* Brandenburg B et al). 2005;42:1300-1309
Schwartz ME (*see* Schiano TD et al). 2005;42:1420-1428
Schwarz M (*see* Stahl S et al). 2005;42:353-361
Schwimmer JB, Behling C, Newbury R, Deutsch R, Nievergelt C, Schork NJ, Lavine JE. Histopathology of pediatric nonalcoholic fatty liver disease. 2005;42:641-649
Sebagh M (*see* Guettier C et al). 2005;42:35-43
Seddaiu MA (*see* Pascale RM et al). 2005;42:1310-1319
Seeff LB (*see* Heller T and Seeff LB). 2005;42:1261-1263 (Editorial)
Seidel N, Volkmann X, Länger P, Manns MP, Schulze-Osthoff K, Bantel H. The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum. 2005;42:113-120
Selmi C (*see* Gershwin ME et al). 2005;42:1194-1202
— (*see* Mao TK et al). 2005;42:802-808
Semendric L (*see* Helbig KJ et al). 2005;42:702-710
Sentilhes L, Verspyck E, Roman H, Marpeau L. Intrahepatic cholestasis of pregnancy and bile acid levels. 2005;42:737-738 (Correspondence)
Senzolo M, Cholongitas E, Patch D, Burroughs AK. TIPS for veno-occlusive disease: Is the contraindication real? 2005;42:240-241 (Correspondence)
Severi T (*see* Laleman W et al). 2005;42:1382-1390
Shafritz DA (*see* Nierhoff D et al). 2005;42:130-139
Shah AB (*see* Katz SC et al). 2005;42:293-300
Shah V (*see* Dunn W et al). 2005;42:495-496 (Reply)
Shah VH (*see* Langer DA and Shah VH). 2005;42:1255-1257 (Editorial)
Shakil AO (*see* Larson AM et al). 2005;42:1364-1372
Shao RX (*see* Kato N et al). 2005;42:846-853
Sharma UC (*see* Bogdanos DP et al). 2005;42:458-465
Shata MTM (*see* Youn YW et al). 2005;42:1429-1436
She H (*see* Deng Q et al). 2005;42:905-914
Shelton M (*see* González-Peralta RP et al). 2005;42:1010-1018
Sherman M. Diagnosis of small hepatocellular carcinoma. 2005;42:14-16 (Editorial)
— (*see* Bruix J and Sherman M). 2005;42:1208-1236 (AASLD Practice Guideline)
Sherratt RM (*see* Montagnese S et al). 2005;42:772-781
Shevade S (*see* Nam SW et al). 2005;42:809-818
Shiina S (*see* Kato N et al). 2005;42:846-853
Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. 2005;42:688-695
Shimizu Y (*see* Nakayama Y et al). 2005;42:915-924
Shimizu YK (*see* Schofield DJ et al). 2005;42:1055-1062
Shimoda S (*see* Mao TK et al). 2005;42:802-808
Shin-I T (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Shiratori K (*see* Yamauchi K et al). 2005;42:149-155
Shneider BL (*see* Balistreri WF et al). 2005;42:222-235 (Special Article)
Sho M (*see* Kuzumoto Y et al). 2005;42:608-617
Shrikhande GV (*see* Longo CR et al). 2005;42:156-164
Siegmund SV (*see* Schwabe RF and Siegmund SV). 2005;42:975-976 (Correspondence)
Simile MM (*see* Pascale RM et al). 2005;42:1310-1319
Simmonds P, Bukh J, Combet C, Deléage G, Enomoto N, Feinstone S, Halfon P, Inchauspé G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. Consensus proposals for a unified

system of nomenclature of hepatitis C virus genotypes. 2005;42:962-973 (Special Article)
Simon MT (*see* Lieu HT et al). 2005;42: 618-626
Singhal S (*see* Forrest E et al). 2005;42:495 (Correspondence)
Skarpen E (*see* Rosseland CM et al). 2005; 42:200-207
Slooff MJH (*see* Geuken E et al). 2005;42: 1166-1174
Smakman N (*see* van der Bilt JDW et al). 2005;42:165-175
Smirne C (*see* Colletta C et al). 2005;42: 838-845
Smith J (*see* Montagnese S et al). 2005;42: 772-781
Sokol RJ (*see* Feranchak AP et al). 2005;42: 782-792
Solá S, Amaral JD, Castro RE, Ramalho RM, Borralho PM, Kren BT, Tanaka H, Steer CJ, Rodrigues CMP. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes. 2005;42:925-934
Soloski MJ (*see* Li Z et al). 2005;42:880-885
Sommer G (*see* Hass M et al). 2005;42:93-103
Song XZ (*see* Yu XX et al). 2005;42:362-371
Soroka CJ (*see* Ballatori N et al). 2005;42: 1270-1279
Soubrane O (*see* Lieu HT et al). 2005;42: 618-626
Soudeyns H (*see* Marceau G et al). 2005; 42:675-682
Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, von Weizsäcker F, Blum HE, Thimme R. Intrahepatic $CD8^+$ T-cell failure during chronic hepatitis C virus infection. 2005;42: 828-837
Spiegel S (*see* Dent P et al). 2005;42:1291-1299
Srivastava S and Younossi ZM. Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery. 2005; 42:490-492 (Hepatology *Elsewhere*)
Stadlmann S (*see* Zoller H et al). 2005;42: 466-472
Stahl S, Ittrich C, Marx-Stoelting P, Köhle C, Altug-Teber Ö, Riess O, Bonin M, Jobst J, Kaiser S, Buchmann A, Schwarz M. Genotype-phenotype relationships in hepatocellular tumors from mice and man. 2005;42:353-361
Steer CJ (*see* Solá S et al). 2005;42:925-934
Steffy KR (*see* Horsmans Y et al). 2005;42: 724-731
Steinbach JH (*see* Hofmann AF et al). 2005;42:1391-1398
Sterling RK (*see* Lok ASF et al). 2005;42: 282-292
Stockl L (*see* Brandenburg B et al). 2005; 42:1300-1309
Stolz DB (*see* Lagoa CE et al). 2005;42: 390-399
Stoyanovsky D (*see* Chen T et al). 2005;42: 598-607
Streetz KL (*see* Wuestefeld T et al). 2005; 42:1082-1090, 1472 (Correction)
Strickland GT (*see* Mohamed MK et al). 2005;42:683-687
Studer E (*see* Dent P et al). 2005;42:1291-1299
Stuyver LJ (*see* Simmonds P et al). 2005; 42:962-973 (Special Article)
Su GL (*see* Marrero JA et al). 2005;42:739-740 (Reply)
Suchy FJ (*see* Balistreri WF et al). 2005;42: 222-235 (Special Article)
Sugiyama T (*see* Nakayama Y et al). 2005; 42:915-924
Sulkowski M (*see* Mehta S et al). 2005;42: 498-499 (Reply)
Sullivan D (*see* Hilmer SN et al). 2005;42: 1349-1354
Sun D (*see* Wang G et al). 2005;42:871-879
Sun DW (*see* Longo CR et al). 2005;42: 156-164
Sun Z (*see* Nagakawa Y et al). 2005;42: 208-215
Sung YC (*see* Youn YW et al). 2005;42: 1429-1436
Suri D (Rigopoulou EI et al). 2005;42: 1028-1036
Sutton A (*see* Robin MA et al). 2005;42: 1280-1290
Svegliati-Baroni G, Inagaki Y, Rincon-Sanchez AR, Else C, Saccomanno S, Benedetti A, Ramirez F, Rojkind M. Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent. 2005;42: 343-352
Swain MG (*see* Zhou F et al). 2005;42: 372-380
Sykora J (*see* Ganten TM et al). 2005;42: 588-597
Sypsa VA, Mimidis K, Tassopoulos NC, Chrysagis D, Vassiliadis T, Moulakakis A, Raptopoulou M, Haida C, Hatzakis A. A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative. 2005;42:77-85
Szondy Z (*see* Sarang Z et al). 2005;42: 578-587

T

Taïeb D, Malicet C, Garcia S, Rocchi P, Arnaud C, Dagorn JC, Iovanna JL, Vasseur S. Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity. 2005;42: 176-182
Takahashi S (*see* Tsuge M et al). 2005;42: 1046-1054
Takaishi H (*see* Tsuge M et al). 2005;42: 1046-1054
Takatsu K (*see* Yamauchi K et al). 2005;42: 149-155
Talwalkar JA. Determining the extent of quality health care for hospitalized patients with cirrhosis. 2005;42:492-494 (Hepatology *Elsewhere*)
Tan Y (*see* Costa RH et al). 2005;42:1004-1008 (Editorial)
Tanaka H (*see* Solá S et al). 2005;42:925-934
Taniguchi H (*see* Kato N et al). 2005;42: 846-853
Targher G. Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease. 2005; 42:974-975 (Correspondence)
Tassopoulos NC (*see* Sypsa VA et al). 2005;42:77-85
Tateno C (*see* Tsuge M et al). 2005;42: 1046-1054
Taub R (*see* DeAngelis RA et al). 2005;42: 1148-1157
te Velde EA (*see* van der Bilt JDW et al). 2005;42:165-175
Tedder RS (Rigopoulou EI et al). 2005;42: 1028-1036
Teratani T (*see* Yamamoto Y et al). 2005; 42:558-567
Ternisien C (*see* Calès P et al). 2005;42: 1373-1381
Teutsch HF. The modular microarchitecture of human liver. 2005;42:317-325
Theurl I (*see* Zoller H et al). 2005;42:466-472
Thibaudeau J (*see* Girard H et al). 2005;42: 448-457
Thiel HJ (*see* Simmonds P et al). 2005;42: 962-973 (Special Article)
Thimme R (*see* Spangenberg HC et al). 2005;42:828-837
Thomas D (*see* Mehta S et al). 2005;42: 498-499 (Reply)
Thomas DL (*see* Cox AL et al). 2005;42: 104-112
Thomas M (*see* Pawlik TM et al). 2005;42: 738-739 (Correspondence)
Thoresen GH (*see* Rosseland CM et al). 2005;42:200-207
Thorgeirsson SS (*see* Pascale RM et al). 2005;42:1310-1319
Thung SN (*see* Schiano TD et al). 2005; 42:1420-1428
Tian J (*see* Columbano A et al). 2005;42: 1118-1126
Tien PC (*see* Monto A et al). 2005;42:310-316
Tiret E (*see* Chignard N et al). 2005;42: 549-557
Tiribelli C (*see* Bedogni G et al). 2005;42: 44-52

— (*see* Ostrow JD and Tiribelli C). 2005; 42:977-978 (Correspondence)
To YF (*see* Chong WP et al). 2005;42: 1037-1045
Tobler LH (*see* Mosley JW et al). 2005;42: 86-92
Tognella P (*see* Montagnese S et al). 2005; 42:772-781
Tokushige K (*see* Yamauchi K et al). 2005; 42:149-155
Toniutto P (*see* Colletta C et al). 2005;42: 838-845
Tralhao JG (*see* Lieu HT et al). 2005;42: 618-626
Trauner M (*see* Wagner M et al). 2005;42: 420-430
Trautwein C (*see* Wuestefeld T et al). 2005;42:1082-1090, 1472 (Correction)
Tricottet V (*see* Guettier C et al). 2005;42: 35-43
Trivin F (*see* Bellodi-Privato M et al). 2005;42:431-438
Trotter J (*see* Everson GT et al). 2005;42: 255-262 (Rapid Communication)
Tseng JH (*see* Yeh TS et al). 2005;42:657-664
Tsuchida A (*see* Nagakawa Y et al). 2005; 42:208-215
Tsuge M, Hiraga N, Takaishi H, Noguchi C, Oga H, Imamura M, Takahashi S, Iwao E, Fujimoto Y, Ochi H, Chayama K, Tateno C, Yoshizato K. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus. 2005;42: 1046-1054
Tsui TY, Lau CK, Ma J, Wu X, Wang YQ, Farkas S, Xu R, Schlitt HJ, Fan ST. rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats. 2005;42:335-342
Tsukamoto H (*see* Deng Q et al). 2005;42: 905-914
Tsurui Y (*see* Kuzumoto Y et al). 2005;42: 608-617
Tucci FA (*see* Sansanno D et al). 2005;42: 1019-1027
Turley SD (*see* Beltroy EP et al). 2005;42: 886-893
Tzourmakliotis D (*see* Papatheodoridis GV et al). 2005;42:121-129

U

Uematsu F (*see* Powell CL et al). 2005;42: 1137-1147
USA PBC Epidemiology Group (*see* Gershwin ME et al). 2005;42:1194-1202
Ustinova E (*see* Lagoa CE et al). 2005;42: 390-399
Utts J (*see* Gershwin ME et al). 2005;42: 1194-1202

V

Valer P (*see* Ruiz-del-Arbol L et al). 2005; 42:439-447
van Bömmel F and Berg T. Reactivation of viral replication after replacement of tenofovir by adefovir. 2005;42:239-240 (Correspondence)
Van de Casteele M (*see* Laleman W et al). 2005;42:1382-1390
van der Bilt JDW, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, te Velde EA, Voest EE, van Diest PJ, Borel Rinkes IHM. Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastasis in a highly standardized murine model. 2005;42:165-175
van Diest PJ (*see* van der Bilt JDW et al). 2005;42:165-175
van Erpecum KJ (*see* Venneman NG and van Erpecum KJ). 2005;42:736-737 (Reply)
Van Huffel S (*see* Wullaert A et al). 2005; 42:381-389
Van Landeghem L (*see* Laleman W et al). 2005;42:1382-1390
van Pelt J (*see* Laleman W et al). 2005;42: 1382-1390
Vander Elst I (*see* Laleman W et al). 2005; 42:1382-1390
VanMeter A (*see* Younossi ZM et al). 2005; 42:665-674
Vanni E (*see* Villanova N et al). 2005;42: 473-480
Vasseur S (*see* Taïeb D et al). 2005;42:176-182
Vassiliadis T (*see* Sypsa VA et al). 2005;42: 77-85
Vauthey JN (*see* Pawlik TM et al). 2005; 42:738-739 (Correspondence)
Veenendaal LM (*see* van der Bilt JDW et al). 2005;42:165-175
Venneman NG and van Erpecum KJ. Small gallstones and pancreatitis. 2005;42:736-737 (Reply)
Venturi AM (*see* Bolondi L et al). 2005;42: 27-34
Vergani D (*see* Bogdanos DP et al). 2005; 42:458-465
Vergara S (*see* Macías J et al). 2005;42:498 (Correspondence)
Verma S and Redeker A. In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? 2005;42:1237 (Correspondence)
Verspyck E (*see* Sentilhes L et al). 2005;42: 737-738 (Correspondence)
Viazov S (*see* Simmonds P et al). 2005;42: 962-973 (Special Article)
— (*see* Spangenberg HC et al). 2005;42: 828-837
Vierling JM (*see* Gershwin ME et al). 2005; 42:1194-1202
Viganò M (*see* Lampertico P et al). 2005; 42:1414-1419
Villanova N, Moscatiello S, Ramilli S, Bugianesi E, Magalotti D, Vanni E, Zoli M, Marchesini G. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. 2005;42:473-480
Villeneuve JP (*see* Huet PM and Villeneuve JP). 2005;42:1248-1251 (Editorial)
Villeneuve L (*see* Girard H et al). 2005;42: 448-457
Violi V (*see* Costi R et al). 2005;42:736 (Correspondence)
Visser DS (*see* Geuken E et al). 2005;42: 1166-1174
Vizzutti F (*see* Aleffi S et al). 2005;42: 1339-1348
Vlachogiannakos J (*see* Bogdanos DP et al). 2005;42:458-465
Vodovotz Y (*see* Lagoa CE et al). 2005;42: 390-399
Voest EE (*see* van der Bilt JDW et al). 2005;42:165-175
Vogel W (*see* Zoller H et al). 2005;42:466-472
Vohra BPS (*see* Wang H et al). 2005;42: 1099-1108
Volkmann X (*see* Seidel N et al). 2005;42: 113-120
von Moltke LL (*see* Girard H et al). 2005; 42:448-457
von Weizsäcker F (*see* Rösler C et al). 2005; 42:301-309
— (*see* Spangenberg HC et al). 2005;42: 828-837

W

Wagner M, Halilbasic E, Marschall HU, Zollner G, Fickert P, Langner C, Zatloukal K, Denk H, Trauner M. CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. 2005;42:420-430
Walczak H (*see* Ganten TM et al). 2005; 42:588-597
— (*see* Herzer K et al). 2005;42:183-192
Walewski JL (*see* Schiano TD et al). 2005; 42:1420-1428
Wan MB (*see* Zeng MD et al). 2005;42: 1437-1445
Wan Q (*see* Zhang T et al). 2005;42:819-827
Wang DQH (*see* Wang HH and Wang DQH). 2005;42:894-904
Wang G, Gong Y, Anderson J, Sun D, Minuk G, Roberts MS, Burczynski FJ. Antioxidant function of L-FABP in L-FABP stably transfected Chang liver cells. 2005;42:871-879
Wang H, Vohra BPS, Zhang Y, Heuckeroth RO. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. 2005;42: 1099-1108
Wang HH and Wang DQH. Reduced

susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine. 2005;42:894-904
Wang IC (*see* Costa RH et al). 2005;42:1004-1008 (Editorial)
Wang JY (*see* Zeng MD et al). 2005;42:1437-1445
Wang X, Lu Y, Cederbaum AI. Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice. 2005;42:400-410
Wang XM, Yu DMT, McCaughan GW, Gorrell MD. Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line. 2005;42:935-945
Wang Y (*see* Kato N et al). 2005;42:846-853
Wang YJ (*see* Zhang T et al). 2005;42:819-827
Wang YQ (*see* Tsui TY et al). 2005;42:335-342
Wanless IR (*see* Feld JJ et al). 2005;42:53-62
Watanbe A (*see* Nakayama Y et al). 2005;42:915-924
Watnik M (*see* Gershwin ME et al). 2005;42:1194-1202
Weill B (*see* Lieu HT et al). 2005;42:618-626
Weiner AJ (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Wenger DE (*see* Zein CO et al). 2005;42:762-771
Werneburg NW (*see* Isomoto H et al). 2005;42:1329-1338
Werner H (*see* Rosseland CM et al). 2005;42:200-207
West AB (*see* Combes B et al). 2005;42:1184-1193
Wettstein M (*see* Görg B et al). 2005;42:499 (Correspondence)
Wheeler DE (*see* Combes B et al). 2005;42:1184-1193
Widell A (*see* Simmonds P et al). 2005;42:962-973 (Special Article)
Wiegard C, Frenzel C, Herkel J, Kallen KJ, Schmitt E, Lohse AW. Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells. 2005;42:193-199
Wielockx B (*see* Wullaert A et al). 2005;42:381-389
Wierød L (*see* Rosseland CM et al). 2005;42:200-207
Wiesner RH (*see* Dunn W et al). 2005;42:495-496 (Reply)
Wilkens L (*see* Plentz RR et al). 2005;42:522-526 (Rapid Communication)
Williams GM (*see* Nagakawa Y et al). 2005;42:208-215
Williams R (Rigopoulou EI et al). 2005;42:1028-1036
Wong F. Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges? 2005;42:533-535 (Editorial)
— (*see* Campbell MS et al). 2005;42:635-640
Wong WHS (*see* Chong WP et al). 2005;42:1037-1045
Worman HJ (*see* Gershwin ME et al). 2005;42:1194-1202
Wright EC (*see* Lok ASF et al). 2005;42:282-292
Wright TL (*see* Monto A et al). 2005;42:310-316
Wu JC (*see* Huo TI et al). 2005;42:238-239 (Correspondence)
Wu X (*see* Tsui TY et al). 2005;42:335-342
Wuestefeld T, Klein C, Streetz KL, Beraza N, Schölmerich J, Burgart LJ, Zender L, Kubicka S, Baskin-Bey E, Gores GJ, Manns MP, Trautwein C. Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice. 2005;42:1082-1090, 1472 (Correction)
Wullaert A, Wielockx B, Van Huffel S, Bogaert V, De Geest B, Papeleu P, Schotte P, El Bakkouri K, Heyninck K, Libert C, Beyaert R. Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality. 2005;42:381-389

X

Xiao SY (*see* Lau DTY et al). 2005;42:273-281
Xiong S (*see* Deng Q et al). 2005;42:905-914
Xu R (*see* Ma H et al). 2005;42:1355-1363
— (*see* Tsui TY et al). 2005;42:335-342

Y

Yamaguchi N (*see* Yamauchi K et al). 2005;42:149-155
Yamamoto H (*see* Yamamoto Y et al). 2005;42:558-567
Yamamoto Y, Teratani T, Yamamoto H, Quinn G, Murata S, Ikeda R, Kinoshita K, Matsubara K, Kato T, Ochiya T. Recapitulation of *in vivo* gene expression during hepatic differentiation from murine embryonic stem cells. 2005;42:558-567
Yamauchi K, Yamaguchi N, Furukawa T, Takatsu K, Nakanishi T, Ishida K, Komatsu T, Tokushige K, Nagahara H, Hashimoto E, Shiratori K. A murine model of acute liver injury induced by human monoclonal antibody. 2005;42:149-155
Yang R (*see* Lagoa CE et al). 2005;42:390-399
Yang SH (*see* Youn YW et al). 2005;42:1429-1436
Yeh TS, Tseng JH, Chen TC, Liu NJ, Chiu CT, Jan YY, Chen MF. Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions. 2005;42:657-664
Yin XM. NADPH oxidase-dependent reactive oxygen species are important to the early stage of CD95 engagement in hepatocytes. 2005;42:956-958 (Hepatology *Elsewhere*)
Yoshizato K (*see* Tsuge M et al). 2005;42:1046-1054
You M, Considine RV, Leone TC, Kelly DP, Crabb DW. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. 2005;42:568-577
You NJ (*see* Nam SW et al). 2005;42:809-818
You S (*see* Rice CM and You S). 2005;42:1456-1458 (Hepatology *Elsewhere*)
Youn YW, Park SH, Lavillette D, Cosset FL, Yang SH, Lee CG, Jin HT, Kim CM, Shata MTM, Lee DH, Pfahler W, Prince AM, Sung YC. Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee. 2005;42:1429-1436
Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A, Ong JP, Goodman Z, Chandhoke V. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. 2005;42:665-674
— (*see* Srivastava S and Younossi ZM). 2005;42:490-492 (Hepatology *Elsewhere*)
Younoszai A (*see* Younossi ZM et al). 2005;42:665-674
Yu DMT (*see* Wang XM et al). 2005;42:935-945
Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. 2005;42:362-371
Yuen MF (*see* Chong WP et al). 2005;42:1037-1045

Z

Zafrani ES (*see* Hézode C et al). 2005;42:63-71
Zakhari S and Hoofnagle JH. Research opportunities on alcohol and liver damage. 2005;42:1243 (This Month from the NIH)
Zakko SF (*see* Hofmann AF et al). 2005;42:1391-1398

Zatloukal K (*see* Wagner M et al). 2005;42: 420-430
Zavala F (*see* Lieu HT et al). 2005;42:618-626
Zeegers M (*see* Laleman W et al). 2005;42: 1382-1390
Zein CO, Jorgensen RA, Clarke B, Wenger DE, Keach JC, Angulo P, Lindor KD. Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial. 2005;42:762-771
Zelcer N (*see* Manautou JE et al). 2005;42: 1091-1098
Zender L (*see* Wuestefeld T et al). 2005;42: 1082-1090, 1472 (Correction)
Zeng MD, Lu LG, Mao YM, Qiu DK, Li JQ, Wan MB, Chen CW, Wang JY, Cai X, Gao CF, Zhou XQ. Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model. 2005;42:1437-1445
Zetterman RK (*see* Combes B et al). 2005; 42:1184-1193
Zeuzem S (*see* Perelson AS et al). 2005;42: 749-754 (Concise Review in Mechanisms of Disease)
Zhang T, Lin RT, Li Y, Douglas SD, Maxcey C, Ho C, Lai JP, Wang YJ, Wan Q, Ho WZ. Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines. 2005;42:819-827
Zhang Y (*see* Wang H et al). 2005;42: 1099-1108
Zheng D (*see* Ma H et al). 2005;42:1355-1363
Zheng Q (*see* Nagakawa Y et al). 2005;42: 208-215
Zhou F, Ajuebor MN, Beck PL, Le T, Hogaboam CM, Swain MG. CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. 2005;42:372-380
Zhou XQ (*see* Zeng MD et al). 2005;42: 1437-1445
Ziegler K (*see* Younossi ZM et al). 2005;42: 665-674
Zoli M (*see* Villanova N et al). 2005;42: 473-480
Zoller H, McFarlane I, Theurl I, Stadlmann S, Nemeth E, Oxley D, Ganz T, Halsall DJ, Cox TM, Vogel W. Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease. 2005;42: 466-472
Zollner G (*see* Wagner M et al). 2005;42: 420-430

Subject Index to Volume 42*

A

A20
A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism (Longo et al). 2005;42:156-164

ABIN-1 (A20 binding inhibitor of NF-κB)
Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389
Hepatology Highlights (Alter). 2005;42:248

Acetaldehyde
Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent (Svegliati-Baroni et al). 2005;42:343-352

Acetaminophen
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study (Larson et al). 2005;42:1364-1372
Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene (Manautou et al). 2005;42:1091-1098
Broadening the view of acetaminophen hepatotoxicity (O'Grady). 2005;42:1252-1254 (Editorial)
Hepatology Highlights (Kaplowitz). 2005;42:986
HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice (Lieu et al). 2005;42:618-626

Acute hepatitis C
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (Cox et al). 2005;42:104-112

Acute inflammation
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation (Coulouarn et al). 2005;42:946-955

Acute liver failure
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study (Larson et al). 2005;42:1364-1372
Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389

Acute liver injury
A murine model of acute liver injury induced by human monoclonal antibody (Yamuchi et al). 2005;42:149-155

Acyl-coenzyme A:diacylglycerol acyltransferase 2 (DGAT2)
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42:362-371

Adefovir
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine (Lampertico et al). 2005;42:1414-1419
Reactivation of viral replication after replacement of tenofovir by adefovir (van Bömmel and Berg). 2005;42:239-240 (Correspondence)

Adeno-associated virus
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363

Adeno-associated virus, recombinant
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats (Tsui et al). 2005;42:335-342

Adipokines
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease (Musso et al). 2005;42:1175-1183

Adiponectin
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? (Anania). 2005;42:530-532 (Editorial)
Hepatology Highlights (Elias). 2005;42:1241
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577

Aging
Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat (Hilmer et al). 2005;42:1349-1354
Microcirculation of the aging liver: Is getting old like having cirrhosis? (Huet and Villeneuve). 2005;42:1248-1251 (Editorial)

AKT
Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes (Dent et al). 2005;42:1291-1299
Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver (Osawa et al). 2005;42:1320-1328

Alanine aminotransferase
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005;42:650-656

Alanine aminotransferase, serum
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42:1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005;42:1461 (Reply)

Albumin
Hepatology Highlights (Elias). 2005;42:512-513
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis (Fernández et al). 2005;42:627-634

Alcohol
Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290
Research opportunities on alcohol and liver damage (Zakhari and Hoofnagle). 2005;42:1243 (This Month From NIH)

Alendronate
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial (Zein et al). 2005;42:762-771

Alpha-1-antitrypsin (α1AT) deficiency
Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease (Rudnick and Perlmutter). 2005;42:514-521 (Concise Review in Mechanisms of Disease)

American Association for the Study of Liver Diseases (AASLD)
AASLD 2005 Distinguished Achievement Award to Dr. Jenny

*July, 1-246; August, 247-510; September, 511-744; October, 745-984; November, 985-1240; December, 1241-1512.

Heathcote (Lee). 2005;42:1244-1245 (2005 AASLD Awardees)
AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff (Hoofnagle). 2005;42:1246-1247 (2005 AASLD Awardees)

American Association for the Study of Liver Diseases (AASLD) practice guidelines

Management of hepatocellular carcinoma (Bruix and Sherman). 2005;42:1208-1236 (AASLD Practice Guideline)

American Association for the Study of Liver Diseases (AASLD)-Sponsored Pediatric Single-Topic Conference

Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference (Balistreri et al). 2005;42:222-235 (Special Article)

Amino acids

A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

Aminotransferase

Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases (Colletta et al). 2005;42:838-845

Aneuploidy

Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma (Plentz et al). 2005;42:522-526 (Rapid Communication)

Angiogenesis

The potential of angiogenesis soluble markers in chronic hepatitis C (Salcedo et al). 2005;42:696-701

Angiopoietin-2 (Ang-2)

The potential of angiogenesis soluble markers in chronic hepatitis C (Salcedo et al). 2005;42:696-701

Animal models

A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism (Longo et al). 2005;42:156-164

Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389

Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat (Hilmer et al). 2005;42:1349-1354

Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290

Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene (Manautou et al). 2005;42:1091-1098

Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42:362-371

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430

CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice (Moreno et al). 2005;42:854-862

CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380

Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease (Beltroy et al). 2005;42:886-893

CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924

Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207

Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885

Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice (Bertolino et al). 2005;42:1063-1071

Gadd45β is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia (Columbano et al). 2005;42:1118-1126

Genotype-phenotype relationships in hepatocellular tumors from mice and man (Stahl et al). 2005;42:353-361

Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity (Chen et al). 2005;42:598-607

Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice (Benten et al). 2005;42:140-148

Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat (Benten et al). 2005;42:1072-1081

Hepatology Highlights (Kaplowitz). 2005;42:986

A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα (DeAngelis et al). 2005;42:1148-1157

HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice (Lieu et al). 2005;42:618-626

Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver (Paku et al). 2005;42:863-870

Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity (Taïeb et al). 2005;42:176-182

Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus (Tsuge et al). 2005;42:1046-1054

Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastasis in a highly standardized murine model (van der Bilt et al). 2005;42:165-175

Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice (Wuestefeld et al). 2005;42:1082-1090

Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis (Muñoz et al). 2005;42:411-419

Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells (Wiegard et al). 2005;42:193-199

A murine model of acute liver injury induced by human monoclonal antibody (Yamuchi et al). 2005;42:149-155

Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934

Of mice and women: toward a mouse model of autoimmune hepatitis (Heneghan and McFarlane). 2005;42:17-20 (Editorial)

Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363

Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005;42:208-215

Purification and characterization of mouse fetal liver epithelial cells with high in vivo repopulation capacity (Nierhoff et al). 2005;42:130-139
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats (Tsui et al). 2005;42: 335-342
Recapitulation of in vivo gene expression during hepatic differentiation from murine embryonic stem cells (Yamamoto et al). 2005;42:558-567
Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine (Wang and Wang). 2005;42:894-904
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis (Laleman et al). 2005;42: 1382-1396
The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock (Lagoa et al). 2005;42:390-399
The role of nuclear factor κB in late-gestation development in the rat (Embree-Ku and Gruppuso). 2005; 42:326-334
Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver (Osawa et al). 2005;42:1320-1328
Significance and therapeutic potential of prostaglandin E_2 receptor in hepatic ischemia/reperfusion injury in mice (Kuzumoto et al). 2005;42:608-617
Steatohepatitis induced by intragastric overfeeding in mice (Deng et al). 2005;42:905-914
Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors (Bellodi-Privato et al). 2005; 42:431-438
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee (Youn et al). 2005; 42:1429-1436
Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury (Powell et al). 2005;42: 1137-1147
The third gas: H_2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis (Fiorucci et al). 2005;42: 539-548
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587
Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice (Wang et al). 2005;42:1099-1108

Antibodies
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and posses neutralizing activity (Schofield et al). 2005;42: 1055-1062
Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice (Wang, Lu, and Cederbaum). 2005; 42:400-410
LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? (Marceau et al). 2005;42:675-682
A murine model of acute liver injury induced by human monoclonal antibody (Yamuchi et al). 2005;42: 149-155
Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic (Bogdanos et al). 2005;42: 458-465

Antigen-presenting cells
Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells (Wiegard et al). 2005;42:193-199

Antiretroviral therapy
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Macías et al). 2005;42:498 (Correspondence)
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Mehta, Thomas, and Sulkowski). 2005;42: 498-499 (Reply)

Antisense
Hepatology Highlights (Alter). 2005;42: 248

Antisense oligonucleotides
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42: 362-371

Antiviral therapy
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy (Everson et al). 2005;42:255-262 (Rapid Communication)

APOBEC
APOBEC-mediated interference with hepadnavirus production (Rösler et al). 2005;42:301-309

Apolipoprotein B48
Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine (Wang and Wang). 2005;42:894-904

Apoptosis
Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005; 42:935-945
Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934
Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver (Osawa et al). 2005;42:1320-1328
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells (Herzer et al). 2005;42:183-192

L-Arginine
A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

Ascites, refractory
Hepatology Highlights (Elias). 2005;42: 512
Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy (Campbell et al). 2005;42: 635-640

Assessment
Assessment of liver fibrosis: palpate, poke or pulse? (Ghany and Doo). 2005; 42:759-761 (Editorial)

Asymmetric dimethylarginine
A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

Atherosclerosis, carotid
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (Targher). 2005;42:974-975 (Correspondence)
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (McPherson). 2005;42:975 (Reply)

ATP-binding cassette transporter G5
Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients (Geuken et al). 2005;42:1166-1174
ATP-binding cassette transporter G8
Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients (Geuken et al). 2005;42:1166-1174
Autoantibodies
LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? (Marceau et al). 2005;42:675-682
Autoimmune hepatitis
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome (Feld et al). 2005;42:53-62
Of mice and women: toward a mouse model of autoimmune hepatitis (Heneghan and McFarlane). 2005;42:17-20 (Editorial)
Autoimmune hepatitis, type 1
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Verma and Redeker). 2005;42:1237 (Correspondence)
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Feld and Heathcote). 2005;42:1237-1238 (Reply)
Awards
AASLD 2005 Distinguished Achievement Award to Dr. Jenny Heathcote (Lee). 2005;42:1244-1245 (2005 AASLD Awardees)
AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff (Hoofnagle). 2005;42:1246-1247 (2005 AASLD Awardees)

B

B cells
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation (Sansanno et al). 2005;42:1019-1027
Bacterial infection
Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice (Wuestefeld et al). 2005;42:1082-1090
Bacterial peritonitis
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis (Fernández et al). 2005;42:627-634
Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges? (Wong). 2005;42:533-535 (Editorial)
Bile acid
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430
Intrahepatic cholestasis of pregnancy and bile acid levels (Sentilhes et al). 2005;42:737-738 (Correspondence)
Intrahepatic cholestasis of pregnancy and bile acid levels (Glantz, Marschall, and Mattsson). 2005;42:738 (Reply)
Bile acid transport
OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia (Ballatori et al). 2005;42:1270-1279
Bile duct ligation
Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver (Osawa et al). 2005;42:1320-1328
Bile salt export pump (BSEP/ABCB11)
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42:242 (Correction)
Biliary cirrhosis
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis (Laleman et al). 2005;42:1382-1390
Biliary cycle
The biliary cycle of Moritz Schiff (Reuben). 2005;42:500-505 (Landmarks in Hepatology)
Biliary system
Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver (Paku et al). 2005;42:863-870
Bilirubin detoxification
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430
Bilirubin elimination
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430
Blood markers
A novel panel of blood markers to assess the degree of liver fibrosis (Calès et al). 2005;42:1373-1381
Bone mineral density
Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial (Zein et al). 2005;42:762-771

C

Cadaveric donor liver grafts
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors (Schiano et al). 2005;42:1420-1428
Cannabinoid CB1 receptors
Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors (Schwabe). 2005;42:959-961 (Hepatology *Elsewhere*)
Cannabinoid CB2 receptors
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Schwabe and Siegmund). 2005;42:975-976 (Correspondence)
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Mallat, Hezode, and Lotersztajn). 2005;42:976-977 (Reply)
Cannabis
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C (Hézode et al). 2005;42:63-71
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Schwabe and Siegmund). 2005;42:975-976 (Correspondence)
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Mallat, Hezode, and Lotersztajn). 2005;42:976-977 (Reply)
Carbon tetrachloride
Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity (Taïeb et al). 2005;42:176-182
Carcinogen detoxification
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (Girard et al). 2005;42:448-457
Cardiomyopathy
What happens to cirrhotic cardiomyopathy after liver transplantation? (Liu and Lee). 2005;42:1203-1205 (Hepatology *Elsewhere*)
Cardiovascular risk
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Villanova et al). 2005;42:473-480
You've gotta have heart! (Reuben). 2005;42:979-983 (Landmarks in Hepatology)

Caspase
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum (Seidel et al). 2005;42:113-120
CD4
Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors (Katz et al). 2005;42:293-300
Hepatology Highlights (Alter). 2005;42:3
Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells (Wiegard et al). 2005;42:193-199
CD8
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (Cox et al). 2005;42:104-112
Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice (Bertolino et al). 2005;42:1063-1071
Hepatology Highlights (Alter). 2005;42:2-3, 745-746
Intrahepatic $CD8^+$ T-cell failure during chronic hepatitis C virus infection (Spangenberg et al). 2005;42:828-837
CD25
Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells (Wiegard et al). 2005;42:193-199
CD40
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
CD95
NADPH oxidase-dependent reactive oxygen species are important to the early stage of CD95 engagement in hepatocytes (Yin). 2005;42:956-958 (Hepatology *Elsewhere*)
CD154
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
Celecoxib
Safety of short-term administration of celecoxib in decompensated cirrhosis (Campbell and Makar). 2005;42:237 (Correspondence)
Safety of short-term administration of celecoxib in decompensated cirrhosis (Clària and Arroyo). 2005;42:238 (Reply)
Cell adhesion
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005;42:935-945
Cell death
Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease (Beltroy et al). 2005;42:886-893
Hepatology Highlights (Alter). 2005;42:248
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587
Cell differentiation
Recapitulation of in vivo gene expression during hepatic differentiation from murine embryonic stem cells (Yamamoto et al). 2005;42:558-567
Cell division cycle 37 (CDC37)
Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in rat liver carcinogenesis and human liver cancer (Pascale et al). 2005;42:1310-1319
Cell growth
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363
Cell migration
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005;42:935-945
Cell proliferation
A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism (Longo et al). 2005;42:156-164
The CAR nuclear receptor and hepatocyte proliferation (Costa et al). 2005;42:1004-1008 (Editorial)
Chemokine receptor CCR5 deficiency
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice (Moreno et al). 2005;42:854-862
Chemosensitivity
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma (Djojosubroto et al). 2005;42:1127-1136
Children
Comparison of indices of vitamin A status in children with chronic liver disease (Feranchak et al). 2005;42:782-792
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics (González-Peralta et al). 2005;42:1010-1018
Cholangiocarcinoma
Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions (Yeh et al). 2005;42:657-664
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells (Isomoto et al). 2005;42:1329-1338
Cholehepatic cycling
Hepatology Highlights (Elias). 2005;42:1241
Choleresis
Hepatology Highlights (Elias). 2005;42:1241
Cholestasis
Exercising the nuclear option to treat cholestasis: CAR and PXR ligands (Karpen). 2005;42:266-269 (Editorial)
Hepatology Highlights (Elias). 2005;42:1242
Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice (Wang et al). 2005;42:1099-1108
Cholestasis, chronic
Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice (Wuestefeld et al). 2005;42:1082-1090
Cholestasis, intrahepatic
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42:242 (Correction)
Hepatology Highlights (Elias). 2005;42:1241-1242
Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference (Balistreri et al). 2005;42:222-235 (Special Article)
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid (Glantz et al). 2005;42:1399-1405
Intrahepatic cholestasis of pregnancy and bile acid levels (Sentilhes et al). 2005;42:737-738 (Correspondence)
Intrahepatic cholestasis of pregnancy and bile acid levels (Glantz, Marschall, and Mattsson). 2005;42:738 (Reply)
Vagaries of impaired transporter function in PFIC 2 and 3 (Ostrow and Tiribelli). 2005;42:977-978 (Correspondence)
Vagaries of impaired transporter function in PFIC 2 and 3 (Keitel et al). 2005;42:978 (Reply)

Cholesterol
Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease (Beltroy et al). 2005; 42:886-893
Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients (Geuken et al). 2005;42:1166-1174
Cholesterol gallstones
Is the FXR the fix for cholesterol gallstone disease? (Juran and Lazaridis). 2005;42:218-221 (Hepatology *Elsewhere*)
Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine (Wang and Wang). 2005;42:894-904
Chromosomal translocations
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation (Sansanno et al). 2005;42:1019-1027
Chromosome 8
Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma (Plentz et al). 2005;42:522-526 (Rapid Communication)
Chronic liver disease
Comparison of indices of vitamin A status in children with chronic liver disease (Feranchak et al). 2005;42: 782-792
Insulin resistance: a metabolic pathway to chronic liver disease (Bugianesi, McCullough, and Marchesini). 2005;42:987-1000 (Concise Review in Mechanisms of Disease)
Milk thistle and chronic liver disease (Hoofnagle). 2005;42:4 (This Month from the NIH)
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: Missed opportunities for vaccination (Shim et al). 2005;42:688-695
Circulatory function
Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between? (McPherson). 2005;42:270-272 (Editorial)
Circulatory function and hepatorenal syndrome in cirrhosis (Ruiz-del-Arbol et al). 2005;42:439-447
Cirrhosis. *See also* Primary biliary cirrhosis
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome (Feld et al). 2005;42:53-62
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma (Bolondi et al). 2005;42: 27-34
Circulatory function and hepatorenal syndrome in cirrhosis (Ruiz-del-Arbol et al). 2005;42:439-447
Determining the extent of quality health care for hospitalized patients with cirrhosis (Talwalkar). 2005;42:492-494 (Hepatology *Elsewhere*)
Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment (Montagnese et al). 2005; 42:772-781
Hepatology Highlights (Alter). 2005;42: 746
Hepatology Highlights (Elias). 2005;42: 513
Hepatology Highlights (Kaplowitz). 2005;42:985
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Verma and Redeker). 2005;42:1237 (Correspondence)
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Feld and Heathcote). 2005;42:1237-1238 (Reply)
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era (Ripoll et al). 2005; 42:793-801
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Libbrecht et al). 2005;42:236 (Correspondence)
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Bañares and Núñez). 2005;42:236-237 (Reply)
Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis (Muñoz et al). 2005;42:411-419
Microcirculation of the aging liver: Is getting old like having cirrhosis? (Huet and Villeneuve). 2005;42: 1248-1251 (Editorial)
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort (Lok et al). 2005; 42:282-292
The third gas: H_2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis (Fiorucci et al). 2005;42: 539-548
What happens to cirrhotic cardiomyopathy after liver transplantation? (Liu and Lee). 2005;42:1203-1205 (Hepatology *Elsewhere*)
Cirrhosis, decompensated
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Brady and Muir). 2005; 42:496-497 (Correspondence)
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Pineda and García-García). 2005;42:497 (Reply)
Safety of short-term administration of celecoxib in decompensated cirrhosis (Campbell and Makar). 2005;42: 237 (Correspondence)
Safety of short-term administration of celecoxib in decompensated cirrhosis (Clària and Arroyo). 2005;42:238 (Reply)
Clinical trials
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)
Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical (Ghanta and Mullen). 2005;42:1206-1207 (Hepatology *Elsewhere*)
α2(I) Collagen
Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent (Svegliati-Baroni et al). 2005;42: 343-352
Complement
Hepatology Highlights (Alter). 2005;42: 247
Constitutive androstane receptor
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430
The CAR nuclear receptor and hepatocyte proliferation (Costa et al). 2005;42:1004-1008 (Editorial)
Exercising the nuclear option to treat cholestasis: CAR and PXR ligands (Karpen). 2005;42:266-269 (Editorial)
Gadd45β is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia (Columbano et al). 2005;42:1118-1126
Hepatology Highlights (Alter). 2005;42: 247-248
Hepatology Highlights (Kaplowitz). 2005;42:986
Cysteines
Hepatology Highlights (Alter). 2005;42: 2

Cytochrome P450 2E1
Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity (Taïeb et al). 2005; 42:176-182
Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice (Wang, Lu, and Cederbaum). 2005; 42:400-410
Cytokeratin 7
Immunohistochemical analysis of cytokeratin 7 expression in resting and proliferating biliary structures of rat liver (Paku et al). 2005;42:863-870
Cytokines
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells (Aleffi et al). 2005;42:1339-1348
Cytotoxic T-lymphocyte antigen-4
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924

D

Dachau concentration camp
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)
Decompensated cirrhosis, HCV-related
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Brady and Muir). 2005; 42:496-497 (Correspondence)
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Pineda and García-García). 2005;42:497 (Reply)
Detoxification
CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Dietrich and Geier). 2005;42:1462 (Correspondence)
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Guillemette and Girard). 2005;42:1463 (Reply)
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (Girard et al). 2005;42:448-457
Dexamethasone
Hepatology Highlights (Elias). 2005;42: 1241-1242
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid (Glantz et al). 2005;42:1399-1405
Diacylglycerol acyltransferase 2
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42: 362-371
Diet, high-fat
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα (DeAngelis et al). 2005;42:1148-1157
Dietary carcinogen detoxification
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (Girard et al). 2005;42:448-457
Dietary factors
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885
Dietary saturated fat
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577
Dimethylarginine
A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis (Laleman et al). 2005;42: 1382-1390
Dionysos Nutrition and Liver Study
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study (Bedogni et al). 2005;42:44-52
DNA, covalently closed circular
Hepatitis B virus cccDNA clearance: killing for curing? (Dandri and Petersen). 2005;42:1453-1455 (Hepatology *Elsewhere*)
DNA, mitochondrial
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215
DNA damage
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215
Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury (Powell et al). 2005;42: 1137-1147
Doctors Trial
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)
Dysplasia
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling (Nam et al). 2005;42:809-818

E

E2 antibody
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee (Youn et al). 2005; 42:1429-1436
E2 glycoprotein
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and posses neutralizing activity (Schofield et al). 2005;42: 1055-1062
Early hepatitis C
Viral and host factors in early hepatitis C virus infection (Mosley et al). 2005; 42:86-92
Egypt
Intrafamilial transmission of hepatitis C in Egypt (Mohamed et al). 2005;42: 683-687
Embryonic stem cells
Recapitulation of in vivo gene expression during hepatic differentiation from murine embryonic stem cells (Yamamoto et al). 2005;42:558-567
Endocannabinoids
Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors (Schwabe). 2005;42: 959-961 (Hepatology *Elsewhere*)
Endothelial cells, sinusoidal
Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice (Benten et al). 2005;42:140-148
Endothelial dysfunction
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Villanova et al). 2005;42:473-480
Epithelial cells
Purification and characterization of mouse fetal liver epithelial cells with high in vivo repopulation capacity (Nierhoff et al). 2005;42:130-139
Eppinger, Hans
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)
Ethanol
Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells (Osna, Clemens, and Donohue, Jr). 2005;42:1109-1117

Ethics
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)
Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical (Ghanta and Mullen). 2005;42:1206-1207 (Hepatology *Elsewhere*)
Extracellular signal-regulated kinase
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207
Extracellular signal-regulated kinase ERK1/2
Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes (Dent et al). 2005;42:1291-1299

F

Familial intrahepatic cholestasis, progressive
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)
Vagaries of impaired transporter function in PFIC 2 and 3 (Ostrow and Tiribelli). 2005;42:977-978 (Correspondence)
Vagaries of impaired transporter function in PFIC 2 and 3 (Keitel et al). 2005;42:978 (Reply)
Farnesoid X receptor
Is the FXR the fix for cholesterol gallstone disease? (Juran and Lazaridis). 2005;42:218-221 (Hepatology *Elsewhere*)
VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium (Chignard et al). 2005; 42:549-557
Fas
Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice (Wang, Lu, and Cederbaum). 2005; 42:400-410
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587
Fat
Fat is an immuno-regulatory issue (Jones). 2005;42:755-758 (Editorial)
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα (DeAngelis et al). 2005;42:1148-1157
Trimming the fat from liver regeneration (Rudnick). 2005;42:1001-1003 (Editorial)
Fat, saturated
Hepatology Highlights (Kaplowitz). 2005;42:985-986
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577
Fatigue
Methodological issues and the measurement of fatigue in primary biliary cirrhosis (Revicki). 2005;42: 24-26 (Editorial)
Fatty liver disease, alcoholic
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? (Anania). 2005;42:530-532 (Editorial)
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577
Fatty liver disease, nonalcoholic
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (Targher). 2005;42:974-975 (Correspondence)
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (McPherson). 2005;42:975 (Reply)
Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between? (McPherson). 2005;42:270-272 (Editorial)
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Villanova et al). 2005;42:473-480
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease (Younossi et al). 2005;42: 665-674
Hepatology Highlights (Elias). 2005;42: 513
Hepatology Highlights (Kaplowitz). 2005;42:986
Histopathology of pediatric nonalcoholic fatty liver disease (Schwimmer et al). 2005;42:641-649
The histopathology of pediatric nonalcoholic fatty liver disease (Molleston). 2005;42:536-538 (Editorial)
Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery (Srivastava and Younossi). 2005;42: 490-492 (Hepatology *Elsewhere*)
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study (Bedogni et al). 2005;42:44-52
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005; 42:650-656
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42: 1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005; 42:1461 (Reply)
Female liver
Male cell microchimerism in normal and diseased female livers from fetal life to adulthood (Guettier et al). 2005; 42:35-43
Ferroportin disease
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease (Zoller et al). 2005;42:466-472
Fetal liver
The role of nuclear factor κB in late-gestation development in the rat (Embree-Ku and Gruppuso). 2005; 42:326-334
Fibroblast activation protein
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005; 42:935-945
Fibrosis
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Macías et al). 2005;42:498 (Correspondence)
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Mehta, Thomas, and Sulkowski). 2005;42: 498-499 (Reply)
Assessment of liver fibrosis: palpate, poke or pulse? (Ghany and Doo). 2005; 42:759-761 (Editorial)
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C (Hézode et al). 2005;42: 63-71
Hepatology Highlights (Alter). 2005;42: 746-747
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. 2005;42:273-281

A novel panel of blood markers to assess the degree of liver fibrosis (Calès et al). 2005;42:1373-1381
Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model (Zeng et al). 2005;42:1437-1445
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats (Tsui et al). 2005;42:335-342
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases (Colletta et al). 2005;42:838-845

Fulminant hepatitis
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924

G

G protein
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587

Gadd45β
Gadd45β is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia (Columbano et al). 2005;42:1118-1126

Galactosamine
Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389

Gallbladder
VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium (Chignard et al). 2005;42:549-557

Gallstones, cholesterol
Is the FXR the fix for cholesterol gallstone disease? (Juran and Lazaridis). 2005;42:218-221 (Hepatology *Elsewhere*)
Reduced susceptibility to cholesterol gallstone formation in mice that do not produce apolipoprotein B48 in the intestine (Wang and Wang). 2005;42:894-904

Gallstones, small
Small gallstones and pancreatitis (Costi et al). 2005;42:736 (Correspondence)
Small gallstones and pancreatitis (Venneman and van Erpecum). 2005;42:736-737 (Reply)

GB virus B
Hepatology Highlights (Alter). 2005;42:3

Gene expression
Recapitulation of in vivo gene expression during hepatic differentiation from murine embryonic stem cells (Yamamoto et al). 2005;42:558-567
Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury (Powell et al). 2005;42:1137-1147

Gene expression profiles
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. 2005;42:273-281
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling (Nam et al). 2005;42:809-818

Gene polymorphisms
A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A (Höhler et al). 2005;42:72-76
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Dietrich and Geier). 2005;42:1462 (Correspondence)
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Guillemette and Girard). 2005;42:1463 (Reply)
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C (Kato et al). 2005;42:846-853
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (Girard et al). 2005;42:448-457

Gene therapy
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363
Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors (Bellodi-Privato et al). 2005;42:431-438

Gene transfer
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle (Brandenburg et al). 2005;42:1300-1309

Genetic engineering
Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus (Tsuge et al). 2005;42:1046-1054

Genetics
Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease (Rudnick and Perlmutter). 2005;42:514-521 (Concise Review in Mechanisms of Disease)

Genomics
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation (Coulouarn et al). 2005;42:946-955
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease (Younossi et al). 2005;42:665-674
Hepatology Highlights (Elias). 2005;42:513

Genotype
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes (Simmonds et al). 2005;42:962-973 (Special Article)

Genotype-phenotype relationships
Genotype-phenotype relationships in hepatocellular tumors from mice and man (Stahl et al). 2005;42:353-361

Glucocorticoid receptor
Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934

Glutamine synthetase
LPS-induced tyrosine nitration of hepatic glutamine synthetase (Görg et al). 2005;42:499 (Correspondence)

Glutathione
Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity (Chen et al). 2005;42:598-607

Glycoprotein 130
Lack of gp130 expression results in more bacterial infection and higher mortality during chronic cholestasis in mice (Wuestefeld et al). 2005;42:1082-1090

GRN163
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma (Djojosubroto et al). 2005;42:1127-1136

GRN163L
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of

human hepatoma (Djojosubroto et al). 2005;42:1127-1136

H

HALT-C cohort
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort (Lok et al). 2005; 42:282-292

Health care
Trends in health care resource use for hepatitis C virus infection in the United States (Grant et al). 2005; 42:1406-1413

Heart
You've gotta have heart! (Reuben). 2005; 42:979-983 (Landmarks in Hepatology)

Heart failure
Hepatology Highlights (Elias). 2005;42: 512

Heat shock protein 90
Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in rat liver carcinogenesis and human liver cancer (Pascale et al). 2005;42: 1310-1319

Heathcote, Jenny
AASLD 2005 Distinguished Achievement Award to Dr. Jenny Heathcote (Lee). 2005;42:1244-1245 (2005 AASLD Awardees)

Heme oxygenase-1
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats (Tsui et al). 2005;42: 335-342

Hemochromatosis type 4
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease (Zoller et al). 2005;42:466-472

Hemorrhagic shock
The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock (Lagoa et al). 2005;42:390-399

Hep3B cells
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation (Coulouarn et al). 2005;42:946-955

Hepadnavirus
APOBEC-mediated interference with hepadnavirus production (Rösler et al). 2005;42:301-309

Hepatic encephalopathy
Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment (Montagnese et al). 2005; 42:772-781
Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical (Ghanta and Mullen). 2005;42:1206-1207 (Hepatology *Elsewhere*)

Hepatic encephalopathy, persistent
High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study (Riggio et al). 2005;42:1158-1165

Hepatic stellate cells
Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent (Svegliati-Baroni et al). 2005;42: 343-352
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat (Benten et al). 2005;42: 1072-1081
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells (Aleffi et al). 2005;42:1339-1348

Hepatic venous pressure gradient
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era (Ripoll et al). 2005; 42:793-801

Hepatitis
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice (Moreno et al). 2005;42:854-862

Hepatitis, alcoholic
Grading alcoholic hepatitis (Forrest et al). 2005;42:495 (Correspondence)
Grading alcoholic hepatitis (Dunn et al). 2005;42:495-496 (Reply)

Hepatitis, autoimmune
Autoimmune hepatitis: effect of symptoms and cirrhosis on natural history and outcome (Feld et al). 2005;42:53-62
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Verma and Redeker). 2005;42:1237 (Correspondence)
In type 1 autoimmune hepatitis, is cirrhosis at presentation or follow-up associated with a poorer outcome? (Feld and Heathcote). 2005;42:1237-1238 (Reply)
Of mice and women: toward a mouse model of autoimmune hepatitis (Heneghan and McFarlane). 2005; 42:17-20 (Editorial)

Hepatitis, fulminant
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924

Hepatitis A
A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A (Höhler et al). 2005;42: 72-76
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination (Shim et al). 2005;42:688-695

Hepatitis B
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine (Lampertico et al). 2005;42:1414-1419
Hepatitis B (Hoofnagle). 2005;42:748 (This Month from the NIH)

Hepatitis B, chronic
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Janssen and Lau). 2005;42:1459 (Correspondence)
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Berg). 2005;42:1459-1460 (Reply)
Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity (Rigopoulou et al). 2005;42:1028-1036
Mannose-binding lectin in chronic hepatitis B virus infection (Chong et al). 2005;42:1037-1045
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine (Papatheodoridis et al). 2005;42: 121-129
Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model (Zeng et al). 2005;42:1437-1445
A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative (Sypsa et al). 2005;42:77-85

Hepatitis B e antigen
Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine (Lampertico et al). 2005;42:1414-1419
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Janssen and Lau). 2005;42:1459 (Correspondence)

Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Berg). 2005;42:1459-1460 (Reply)
Prediction of significant fibrosis in HBeAg-positive patients with chronic hepatitis B by a noninvasive model (Zeng et al). 2005;42:1437-1445

Hepatitis B surface antigen
A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A (Höhler et al). 2005;42:72-76

Hepatitis B virus
Functional analysis of hepatitis B virus reactivating in hepatitis B surface antigen-negative individuals (Hass et al). 2005;42:93-103
Hepatitis B viral kinetics: a dynamic puzzle still to be resolved (Neumann). 2005;42:249-254 (Perspectives in Clinical Hepatology)
Hepatitis B virus cccDNA clearance: killing for curing? (Dandri and Petersen). 2005;42:1453-1455 (Hepatology *Elsewhere*)
Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus (Tsuge et al). 2005;42:1046-1054
A novel target of hepatitis B virus mutations: splicing of surface RNA (Baumert, Kock, and Blum). 2005;42:21-23 (Editorial)
Reactivation of viral replication after replacement of tenofovir by adefovir (van Bömmel and Berg). 2005;42:239-240 (Correspondence)
A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative (Sypsa et al). 2005;42:77-85

Hepatitis B virus-like particle, cell-permeable
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle (Brandenburg et al). 2005;42:1300-1309

Hepatitis C
Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection (Monto et al). 2005;42:310-316
Intrafamilial transmission of hepatitis C in Egypt (Mohamed et al). 2005;42:683-687
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C (Kato et al). 2005;42:846-853
Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland (Hutchinson, Bird, and Goldberg). 2005;42:711-723
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort (Lok et al). 2005;42:282-292
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination (Shim et al). 2005;42:688-695
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee (Youn et al). 2005;42:1429-1436
Treating hepatitis C: Can you teach old dogs new tricks? (Rice and You). 2005;42:1456-1458 (Hepatology *Elsewhere*)
Trends in health care resource use for hepatitis C virus infection in the United States (Grant et al). 2005;42:1406-1413

Hepatitis C, acute
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (Cox et al). 2005;42:104-112

Hepatitis C, advanced
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy (Everson et al). 2005;42:255-262 (Rapid Communication)

Hepatitis C, chronic
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector (Helbig et al). 2005;42:702-710
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Macías et al). 2005;42:498 (Correspondence)
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Mehta, Thomas, and Sulkowski). 2005;42:498-499 (Reply)
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C (Hézode et al). 2005;42:63-71
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum (Seidel et al). 2005;42:113-120
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics (González-Peralta et al). 2005;42:1010-1018
Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection (Spangenberg et al). 2005;42:828-837
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection (Horsmans et al). 2005;42:724-731
LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? (Marceau et al). 2005;42:675-682
The potential of angiogenesis soluble markers in chronic hepatitis C (Salcedo et al). 2005;42:696-701
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Schwabe and Siegmund). 2005;42:975-976 (Correspondence)
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Mallat, Hezode, and Lotersztajn). 2005;42:976-977 (Reply)
Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort (Lok et al). 2005;42:282-292
Viral load as a predictor of progression of chronic hepatitis C? (Heller and Seeff). 2005;42:1261-1263 (Editorial)

Hepatitis C, early
Viral and host factors in early hepatitis C virus infection (Mosley et al). 2005;42:86-92

Hepatitis C virus
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors (Schiano et al). 2005;42:1420-1428
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes (Simmonds et al). 2005;42:962-973 (Special Article)
HCV: alive and kicking in living donor liver grafts? (Forns). 2005;42:1258-1260 (Editorial)
HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation (Sansanno et al). 2005;42:1019-1027
Hepatitis C virus comes full circle: production of recombinant infectious virus in tissue culture (Berke and Moradpour). 2005;42:1264-1269 (Science Frontier)
Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines (Zhang et al). 2005;42:819-827

Hepatitis C virus load and survival among injection drug users in the United States (Hisada et al). 2005; 42:1446-1452
Hepatology Highlights (Alter). 2005;42: 745-746
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and posses neutralizing activity (Schofield et al). 2005;42: 1055-1062
Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection (Horsmans et al). 2005;42:724-731
New kinetic models for the hepatitis C virus (Perelson et al). 2005;42:749-754 (Concise Review in Mechanisms of Disease)
Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases (Colletta et al). 2005;42:838-845
Viral and host factors in early hepatitis C virus infection (Mosley et al). 2005; 42:86-92
Viral load as a predictor of progression of chronic hepatitis C? (Heller and Seeff). 2005;42:1261-1263 (Editorial)

Hepatitis C virus NS3
Hepatology Highlights (Alter). 2005;42: 1

Hepatitis C virus NS5A
Function follows form: the structure of the N-terminal domain of HCV NS5A (Moradpour, Brass, and Penin). 2005;42:732-735 (Hepatology *Elsewhere*)

Hepatitis C virus-induced fibrosis
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. 2005;42:273-281

Hepatitis C virus-related decompensated cirrhosis
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Brady and Muir). 2005; 42:496-497 (Correspondence)
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Pineda and García-García). 2005;42:497 (Reply)

Hepatobiliary transporters
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)

Hepatocarcinoma-intestine-pancreas/ pancreatic-associated protein
Hepatology Highlights (Kaplowitz). 2005;42:985
HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice (Lieu et al). 2005;42: 618-626

Hepatocellular carcinoma
Alpha-1-antitrypsin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease (Rudnick and Perlmutter). 2005;42: 514-521 (Concise Review in Mechanisms of Disease)
Comparison of staging systems for HCC: One more positive answer or mission impossible? (Huo, Wu, and Lee). 2005;42:238-239 (Correspondence)
Genotype-phenotype relationships in hepatocellular tumors from mice and man (Stahl et al). 2005;42:353-361
Hepatology Highlights (Elias). 2005;42: 513
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Libbrecht et al). 2005;42:236 (Correspondence)
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Bañares and Núñez). 2005;42:236-237 (Reply)
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C (Kato et al). 2005;42:846-853
Management of hepatocellular carcinoma (Bruix and Sherman). 2005;42:1208-1236 (AASLD Practice Guideline)
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling (Nam et al). 2005;42:809-818
A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome (Anan and Gores). 2005;42:527-529 (Editorial)
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL (Ganten et al). 2005;42:588-597
Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in rat liver carcinogenesis and human liver cancer (Pascale et al). 2005;42: 1310-1319
Staging of hepatocellular carcinoma (Pawlik et al). 2005;42:738-739 (Correspondence)
Staging of hepatocellular carcinoma (Marrero et al). 2005;42:739-740 (Reply)
Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma (Plentz et al). 2005;42:522-526 (Rapid Communication)

Hepatocellular carcinoma, hypovascular
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma (Bolondi et al). 2005;42: 27-34

Hepatocellular carcinoma, small
Diagnosis of small hepatocellular carcinoma (Sherman). 2005;42:14-16 (Editorial)

Hepatocyte transplantation
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat (Benten et al). 2005;42: 1072-1081

Hepatocytes
A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism (Longo et al). 2005;42:156-164
Activation and function of hepatocyte NF-κB in postischemic liver injury (Lentsch). 2005;42:216-218 (Hepatology *Elsewhere*)
The CAR nuclear receptor and hepatocyte proliferation (Costa et al). 2005;42:1004-1008 (Editorial)
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis (Zhou et al). 2005;42:372-380
Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes (Dent et al). 2005;42:1291-1299
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation (Coulouarn et al). 2005;42:946-955
Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity (Chen et al). 2005;42:598-607
NADPH oxidase-dependent reactive oxygen species are important to the early stage of CD95 engagement in hepatocytes (Yin). 2005;42:956-958 (Hepatology *Elsewhere*)
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like

particle (Brandenburg et al). 2005; 42:1300-1309
Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL (Ganten et al). 2005;42:588-597
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587

Hepatology
Who writes the article? (Blei). 2005;42: 511 (Editor's Corner)

Hepatoma
Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells (Osna, Clemens, and Donohue, Jr). 2005;42:1109-1117
Genome-wide response of the human Hep3B hepatoma cell to proinflammatory cytokines, from transcription to translation (Coulouarn et al). 2005;42:946-955
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma (Djojosubroto et al). 2005;42:1127-1136
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells (Herzer et al). 2005;42:183-192

Hepatorenal syndrome
Circulatory function and hepatorenal syndrome in cirrhosis (Ruiz-del-Arbol et al). 2005;42:439-447
Hepatology Highlights (Elias). 2005;42: 512
Hepatorenal syndrome—Is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction? (Lenz). 2005;42:263-265 (Editorial)

Hepatotoxicity
Broadening the view of acetaminophen hepatotoxicity (O'Grady). 2005;42: 1252-1254 (Editorial)
Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity (Taïeb et al). 2005; 42:176-182

Hepcidin
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease (Zoller et al). 2005;42:466-472

HepG2 cells
Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells (Osna, Clemens, and Donohue, Jr). 2005;42:1109-1117

Hippocratic oath
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)

History
The biliary cycle of Moritz Schiff (Reuben). 2005;42:500-505 (Landmarks in Hepatology)
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)

HIV infection
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Macías et al). 2005;42:498 (Correspondence)
Antiretroviral therapy and liver fibrosis in HIV-infected patients with chronic hepatitis C (Mehta, Thomas, and Sulkowski). 2005;42: 498-499 (Reply)
Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection (Monto et al). 2005;42:310-316
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Brady and Muir). 2005; 42:496-497 (Correspondence)
HIV coinfection shortens the survival of patients with hepatitis C virus–related decompensated cirrhosis (Pineda and García-García). 2005;42:497 (Reply)

Holocaust
First do no harm (Reuben). 2005;42: 1464-1470 (Landmarks in Hepatology)

Hospitalization
Determining the extent of quality health care for hospitalized patients with cirrhosis (Talwalkar). 2005;42:492-494 (Hepatology *Elsewhere*)

Hydrogen sulfide
Hepatology Highlights (Kaplowitz). 2005;42:985
The third gas: H_2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis (Fiorucci et al). 2005;42: 539-548

Hydroxyethyl starch
A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis (Fernández et al). 2005;42:627-634

Hyperbilirubinemia
Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors (Bellodi-Privato et al). 2005; 42:431-438

Hyperlipidemia
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42: 362-371

Hyperplasia
Gadd45β is induced through a CAR-dependent, TNF-independent pathway in murine liver hyperplasia (Columbano et al). 2005;42:1118-1126

I

Immune system
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885

Immunoglobulin
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924

Immunoglobulin G3
Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic (Bogdanos et al). 2005;42: 458-465

Immunoregulation
Fat is an immuno-regulatory issue (Jones). 2005;42:755-758 (Editorial)

Inflammation, systemic
Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis (Muñoz et al). 2005;42:411-419

Inhibitor of nuclear factor-κB alpha
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα (DeAngelis et al). 2005;42:1148-1157

Injection drug users
Hepatitis C virus load and survival among injection drug users in the United States (Hisada et al). 2005; 42:1446-1452

Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland (Hutchinson, Bird, and Goldberg). 2005;42:711-723

Insulin resistance

Insulin resistance: a metabolic pathway to chronic liver disease (Bugianesi, McCullough, and Marchesini). 2005;42:987-1000 (Concise Review in Mechanisms of Disease)

Intercellular adhesion molecule-1

Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice (Bertolino et al). 2005;42:1063-1071

Interferon

Hepatology Highlights (Alter). 2005;42:745

Interferon, pegylated

Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Janssen and Lau). 2005;42:1459 (Correspondence)

Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Berg). 2005;42:1459-1460 (Reply)

Interferon alfa

Hepatitis C virus inhibits intracellular interferon alpha expression in human hepatic cell lines (Zhang et al). 2005;42:819-827

Interferon alfa-2b

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics (González-Peralta et al). 2005;42:1010-1018

Interferon alfa-2b, pegylated

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative (Sypsa et al). 2005;42:77-85

Interferon gamma

Ethanol metabolism alters interferon gamma signaling in recombinant HepG2 cells (Osna, Clemens, and Donohue, Jr). 2005;42:1109-1117

Interferon-stimulated genes

Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector (Helbig et al). 2005;42:702-710

Interleukin-2

Hepatology Highlights (Alter). 2005;42:3

Interleukin-6

Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells (Isomoto et al). 2005;42:1329-1338

Interleukin-10

A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A (Höhler et al). 2005;42:72-76

Interleukin-12

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity (Rigopoulou et al). 2005;42:1028-1036

Intraductal growth-type intrahepatic cholangiocarcinoma

Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions (Yeh et al). 2005;42:657-664

Intrahepatic cholangiocarcinoma

Characterization of intrahepatic cholangiocarcinoma of the intraductal growth-type and its precursor lesions (Yeh et al). 2005;42:657-664

Intrahepatic cholestasis, familial

Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42:242 (Correction)

Vagaries of impaired transporter function in PFIC 2 and 3 (Ostrow and Tiribelli). 2005;42:977-978 (Correspondence)

Vagaries of impaired transporter function in PFIC 2 and 3 (Keitel et al). 2005;42:978 (Reply)

Intrahepatic cholestasis of pregnancy

Hepatology Highlights (Elias). 2005;42:1241-1242

Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid (Glantz et al). 2005;42:1399-1405

Intrahepatic cholestasis of pregnancy and bile acid levels (Sentilhes et al). 2005;42:737-738 (Correspondence)

Intrahepatic cholestasis of pregnancy and bile acid levels (Glantz, Marschall, and Mattsson). 2005;42:738 (Reply)

Iron overload, primary

Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease (Zoller et al). 2005;42:466-472

Isatoribine

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection (Horsmans et al). 2005;42:724-731

Ischemia/reperfusion injury

Activation and function of hepatocyte NF-κB in postischemic liver injury (Lentsch). 2005;42:216-218 (Hepatology *Elsewhere*)

Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastasis in a highly standardized murine model (van der Bilt et al). 2005;42:165-175

Significance and therapeutic potential of prostaglandin E_2 receptor in hepatic ischemia/reperfusion injury in mice (Kuzumoto et al). 2005;42:608-617

Italy

Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study (Bedogni et al). 2005;42:44-52

J

Jo2 antibody

Induction of cytochrome P450 2E1 increases hepatotoxicity caused by Fas agonistic Jo2 antibody in mice (Wang, Lu, and Cederbaum). 2005;42:400-410

L

Lactobacillus

Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic (Bogdanos et al). 2005;42:458-465

Lamivudine

Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine (Lampertico et al). 2005;42:1414-1419

Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity (Rigopoulou et al). 2005;42:1028-1036

Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine (Papatheodoridis et al). 2005;42:121-129

A viral kinetic study using pegylated interferon alfa-2b and/or lamivudine in patients with chronic hepatitis B/HBeAg negative (Sypsa et al). 2005;42:77-85

L-arginine

A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

Leptin

Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells (Aleffi et al). 2005;42:1339-1348

Leukocyte function antigen-1
Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice (Bertolino et al). 2005;42:1063-1071
Lipids
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease (Musso et al). 2005;42:1175-1183
Lipogenesis
Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors (Schwabe). 2005;42: 959-961 (Hepatology *Elsewhere*)
Lipopolysaccharide
LPS-induced tyrosine nitration of hepatic glutamine synthetase (Görg et al). 2005;42:499 (Correspondence)
Lipoprotein transfer
Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat (Hilmer et al). 2005;42:1349-1354
Liver
Microcirculation of the aging liver: Is getting old like having cirrhosis? (Huet and Villeneuve). 2005;42: 1248-1251 (Editorial)
The modular microarchitecture of human liver (Teutsch). 2005;42: 317-325
Liver damage
Research opportunities on alcohol and liver damage (Zakhari and Hoofnagle). 2005;42:1243 (This Month From NIH)
Liver disease
Steatosis: co-factor in other liver diseases (Powell et al). 2005;42:5-13 (Perspectives in Clinical Hepatology)
Liver disease, chronic
Comparison of indices of vitamin A status in children with chronic liver disease (Feranchak et al). 2005;42: 782-792
Insulin resistance: a metabolic pathway to chronic liver disease (Bugianesi, McCullough, and Marchesini). 2005;42:987-1000 (Concise Review in Mechanisms of Disease)
Milk thistle and chronic liver disease (Hoofnagle). 2005;42:4 (This Month from the NIH)
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination (Shim et al). 2005;42:688-695
Liver disease, drug-induced
Outcome and prognostic markers in severe drug-induced liver disease (Björnsson and Olsson). 2005;42: 481-489
Liver disease, fatty
Adiponectin and alcoholic fatty liver: Is it, after all, about what you eat? (Anania). 2005;42:530-532 (Editorial)
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (Targher). 2005;42:974-975 (Correspondence)
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (McPherson). 2005;42:975 (Reply)
Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between? (McPherson). 2005;42:270-272 (Editorial)
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Villanova et al). 2005;42:473-480
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease (Younossi et al). 2005;42: 665-674
Hepatology Highlights (Elias). 2005;42: 513
Hepatology Highlights (Kaplowitz). 2005;42:986
Histopathology of pediatric nonalcoholic fatty liver disease (Schwimmer et al). 2005;42:641-649
The histopathology of pediatric nonalcoholic fatty liver disease (Molleston). 2005;42:536-538 (Editorial)
Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery (Srivastava and Younossi). 2005;42: 490-492 (Hepatology *Elsewhere*)
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study (Bedogni et al). 2005;42:44-52
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005; 42:650-656
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42: 1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005; 42:1461 (Reply)
Liver disease, genetic
Alpha-1-antitrypysin deficiency: a new paradigm for hepatocellular carcinoma in genetic liver disease (Rudnick and Perlmutter). 2005;42: 514-521 (Concise Review in Mechanisms of Disease)
Liver failure, acute
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study (Larson et al). 2005;42:1364-1372
Adenoviral gene transfer of ABIN-1 protects mice from TNF/ galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389
Liver fatty acid binding protein (L-FABP)
Antioxidant function of L-FABP in L-FABP stably transfected Chang liver cells (Wang et al). 2005;42:871-879
Liver grafts
HCV: alive and kicking in living donor liver grafts? (Forns). 2005;42:1258-1260 (Editorial)
Liver injury
CTLA-4Ig suppresses liver injury by inhibiting acquired immune responses in a mouse model of fulminant hepatitis (Nakayama et al). 2005;42:915-924
Temporal correlation of pathology and DNA damage with gene expression in a choline-deficient model of rat liver injury (Powell et al). 2005;42: 1137-1147
Liver injury, acute
A murine model of acute liver injury induced by human monoclonal antibody (Yamuchi et al). 2005;42: 149-155
Liver injury, cholestatic
Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice (Wang et al). 2005;42:1099-1108
Liver injury, postischemic
Activation and function of hepatocyte NF-κB in postischemic liver injury (Lentsch). 2005;42:216-218 (Hepatology *Elsewhere*)
Liver regeneration
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-κB inhibitor, IκBα (DeAngelis et al). 2005;42:1148-1157
HIP/PAP accelerates liver regeneration and protects against acetaminophen injury in mice (Lieu et al). 2005;42: 618-626

Trimming the fat from liver regeneration (Rudnick). 2005;42:1001-1003 (Editorial)

Liver sinusoidal endothelial cells
Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice (Benten et al). 2005;42:140-148

Liver transplantation
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors (Schiano et al). 2005;42:1420-1428
Hepatic expression of ABC transporters G5 and G8 does not correlate with biliary cholesterol secretion in liver transplant patients (Geuken et al). 2005;42:1166-1174
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215
What happens to cirrhotic cardiomyopathy after liver transplantation? (Liu and Lee). 2005;42:1203-1205 (Hepatology *Elsewhere*)

Liver-kidney microsomes type 1
Hepatology Highlights (Alter). 2005;42: 746-747
LKM1 autoantibodies in chronic hepatitis C infection: a case of molecular mimicry? (Marceau et al). 2005;42:675-682

Living donor liver grafts
Accelerated hepatitis C virus kinetics but similar survival rates in recipients of liver grafts from living versus deceased donors (Schiano et al). 2005;42:1420-1428
HCV: Alive and kicking in living donor liver grafts? (Forns). 2005;42:1258-1260 (Editorial)

Low accelerating dosage regimen
Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy (Everson et al). 2005;42:255-262 (Rapid Communication)

LX-2 cells
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005; 42:935-945

M

Mannose-binding lectin
Mannose-binding lectin in chronic hepatitis B virus infection (Chong et al). 2005;42:1037-1045

Metastasis
Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastasis in a highly standardized murine model (van der Bilt et al). 2005;42:165-175

Methotrexate
Hepatology Highlights (Elias). 2005;42: 1242
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (Combes et al). 2005;42: 1184-1193

Methylenetetrahydrofolate reductase
Hepatology Highlights (Alter). 2005;42: 2

Microarchitecture
The modular microarchitecture of human liver (Teutsch). 2005;42: 317-325

Microchimerism, male
Male cell microchimerism in normal and diseased female livers from fetal life to adulthood (Guettier et al). 2005; 42:35-43

Microcirculation
Microcirculation of the aging liver: Is getting old like having cirrhosis? (Huet and Villeneuve). 2005;42: 1248-1251 (Editorial)

Micrometastasis
Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastasis in a highly standardized murine model (van der Bilt et al). 2005;42:165-175

Milk thistle
Milk thistle and chronic liver disease (Hoofnagle). 2005;42:4 (This Month from the NIH)

Mitochondrial DNA
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215

Model for End-Stage Liver Disease (MELD)
Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD era (Ripoll et al). 2005; 42:793-801

Monoclonal antibodies
Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and posses neutralizing activity (Schofield et al). 2005;42: 1055-1062
A murine model of acute liver injury induced by human monoclonal antibody (Yamuchi et al). 2005;42: 149-155

Multidrug resistance protein Mrp3 gene
Altered disposition of acetaminophen in mice with a disruption of the Mrp3 gene (Manautou et al). 2005;42: 1091-1098

Multidrug resistance-associated protein
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)

Mutations
A novel target of hepatitis B virus mutations: splicing of surface RNA (Baumert, Kock, and Blum). 2005; 42:21-23 (Editorial)

Myeloid cell leukemia-1
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells (Isomoto et al). 2005;42:1329-1338

N

NADPH oxidase
NADPH oxidase-dependent reactive oxygen species are important to the early stage of CD95 engagement in hepatocytes (Yin). 2005;42:956-958 (Hepatology *Elsewhere*)

Na^+/taurocholate cotransporter
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)

National Institutes of Health (NIH)
Hepatitis B (Hoofnagle). 2005;42:748 (This Month from the NIH)
Milk thistle and chronic liver disease (Hoofnagle). 2005;42:4 (This Month from the NIH)
Research opportunities on alcohol and liver damage (Zakhari and Hoofnagle). 2005;42:1243 (This Month From NIH)

Niemann-Pick type C disease
Cholesterol accumulation and liver cell death in mice with Niemann-Pick type C disease (Beltroy et al). 2005; 42:886-893

Nitric oxide
A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

Nitric oxide donors
Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity (Chen et al). 2005;42:598-607

Nodules, cirrhotic
Hepatology Highlights (Elias). 2005;42: 513

Nodules, dysplastic
Molecular changes from dysplastic nodule to hepatocellular carcinoma through gene expression profiling (Nam et al). 2005;42:809-818

Nodules, small
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of

hypovascular hepatocellular carcinoma (Bolondi et al). 2005;42: 27-34

Nomenclature
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes (Simmonds et al). 2005; 42:962-973 (Special Article)

Nonalcoholic fatty liver disease
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (Targher). 2005;42:974-975 (Correspondence)
Associations between liver histology and early carotid atherosclerosis in subjects with nonalcoholic fatty liver disease (McPherson). 2005;42:975 (Reply)
Circulatory dysfunction in NAFLD — Which is first, which is last, and what do we do in between? (McPherson). 2005;42:270-272 (Editorial)
Dietary factors alter hepatic innate immune system in mice with nonalcoholic fatty liver disease (Li, Soloski, and Diehl). 2005;42:880-885
Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease (Villanova et al). 2005;42:473-480
A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease (Younossi et al). 2005;42: 665-674
Hepatology Highlights (Elias). 2005;42: 513
Hepatology Highlights (Kaplowitz). 2005;42:986
Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery (Srivastava and Younossi). 2005;42: 490-492 (Hepatology *Elsewhere*)
Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos Nutrition and Liver Study (Bedogni et al). 2005;42:44-52
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005; 42:650-656
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42: 1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005; 42:1461 (Reply)

Nonalcoholic fatty liver disease, pediatric
Histopathology of pediatric nonalcoholic fatty liver disease (Schwimmer et al). 2005;42:641-649
The histopathology of pediatric nonalcoholic fatty liver disease (Molleston). 2005;42:536-538 (Editorial)

Nonalcoholic steatohepatitis
Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease (Musso et al). 2005;42:1175-1183
Hepatology Highlights (Elias). 2005;42: 513, 1241

Norursodeoxycholic acid
Hepatology Highlights (Elias). 2005;42: 1241
Novel biotransformation and physiological properties of norursodeoxycholic acid in humans (Hofmann et al). 2005;42:1391-1398

NS3 protein
Hepatology Highlights (Alter). 2005;42: 1

Nuclear factor-κB
Activation and function of hepatocyte NF-κB in postischemic liver injury (Lentsch). 2005;42:216-218 (Hepatology *Elsewhere*)
Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290
The role of nuclear factor κB in late-gestation development in the rat (Embree-Ku and Gruppuso). 2005; 42:326-334

Nucleos(t)ide analog therapy
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Janssen and Lau). 2005;42:1459 (Correspondence)
Chronic hepatitis B: HBeAg seroconversion after pegylated interferon and nucleos(t)ide analogs (Berg). 2005;42:1459-1460 (Reply)
Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine (Papatheodoridis et al). 2005;42: 121-129

O

Obesity
Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42: 362-371
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005; 42:650-656
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42: 1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005; 42:1461 (Reply)

Obesity, morbid
Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery (Srivastava and Younossi). 2005;42: 490-492 (Hepatology *Elsewhere*)

Oncoretrovirus
Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors (Bellodi-Privato et al). 2005; 42:431-438

Organic anion transporters
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)

Organic solute transporters
OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia (Ballatori et al). 2005;42: 1270-1279

Oval cells
Hepatology Highlights (Alter). 2005;42: 247

Overfeeding
Hepatology Highlights (Kaplowitz). 2005;42:986

Overfeeding, intragastric
Steatohepatitis induced by intragastric overfeeding in mice (Deng et al). 2005;42:905-914

Oxidative stress
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207

P

p8
Inactivation of stress protein p8 increases murine carbon tetrachloride hepatotoxicity via preserved CYP2E1 activity (Taïeb et al). 2005; 42:176-182

$p16^{INK4A}$
Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in

rat liver carcinogenesis and human liver cancer (Pascale et al). 2005;42: 1310-1319

$p21^{waf1}$

A20 protects mice from lethal radical hepatectomy by protecting hepatocyte proliferation via a $p21^{waf1}$-dependent mechanism (Longo et al). 2005;42:156-164

Palpation

Assessment of liver fibrosis: palpate, poke or pulse? (Ghany and Doo). 2005; 42:759-761 (Editorial)

Pancreatitis

Small gallstones and pancreatitis (Costi et al). 2005;42:736 (Correspondence)

Small gallstones and pancreatitis (Venneman and van Erpecum). 2005;42:736-737 (Reply)

Paracentesis

Hepatology Highlights (Elias). 2005;42: 512-513

Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy (Campbell et al). 2005;42: 635-640

Pediatric nonalcoholic fatty liver disease

Histopathology of pediatric nonalcoholic fatty liver disease (Schwimmer et al). 2005;42:641-649

The histopathology of pediatric nonalcoholic fatty liver disease (Molleston). 2005;42:536-538 (Editorial)

Pediatric Single-Topic Conference

Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference (Balistreri et al). 2005; 42:222-235 (Special Article)

Perfusion pressure

The third gas: H_2S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis (Fiorucci et al). 2005;42: 539-548

Peritonitis, bacterial

A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis (Fernández et al). 2005;42:627-634

Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges? (Wong). 2005;42:533-535 (Editorial)

Pertussis toxin

Conjugated bile acids promote ERK1/2 and AKT activation via a pertussis toxin-sensitive mechanism in murine and human hepatocytes (Dent et al). 2005;42:1291-1299

Phenobarbital

Hepatology Highlights (Alter). 2005;42: 247-248

Placeba-controlled treatment trials

Placebo controlled treatment trials in hepatic encephalopathy are feasible and ethical (Ghanta and Mullen). 2005;42:1206-1207 (Hepatology *Elsewhere*)

Plasminogen activator inhibitor type 1

The role of hepatic type 1 plasminogen activator inhibitor (PAI-1) during murine hemorrhagic shock (Lagoa et al). 2005;42:390-399

Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice (Wang et al). 2005;42:1099-1108

Portal hypertension

A gas, an amino acid, and an imposter: the story of nitric oxide, L-arginine, and ADMA in portal hypertension (Langer and Shah). 2005;42:1255-1257 (Editorial)

A role for asymmetric dimethylarginine in the pathophysiology of portal hypertension in rats with biliary cirrhosis (Laleman et al). 2005;42: 1382-1390

Portal-systemic shunts

High prevalence of spontaneous portal-systemic shunts in persistent hepatic encephalopathy: a case-control study (Riggio et al). 2005;42:1158-1165

Pregnancy, intrahepatic cholestasis of

Hepatology Highlights (Elias). 2005;42: 1241-1242

Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid (Glantz et al). 2005;42:1399-1405

Intrahepatic cholestasis of pregnancy and bile acid levels (Sentilhes et al). 2005;42:737-738 (Correspondence)

Intrahepatic cholestasis of pregnancy and bile acid levels (Glantz, Marschall, and Mattsson). 2005;42:738 (Reply)

Pregnane X receptor

CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice (Wagner et al). 2005;42:420-430

Exercising the nuclear option to treat cholestasis: CAR and PXR ligands (Karpen). 2005;42:266-269 (Editorial)

Primary biliary cirrhosis

Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial (Zein et al). 2005;42:762-771

Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis (Mao et al). 2005;42:802-808

Hepatology Highlights (Elias). 2005;42: 1242

Methodological issues and the measurement of fatigue in primary biliary cirrhosis (Revicki). 2005;42: 24-26 (Editorial)

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (Combes et al). 2005;42: 1184-1193

Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its lactobacillus mimic (Bogdanos et al). 2005;42: 458-465

Reflections on therapeutic trials in primary biliary cirrhosis (Combes). 2005;42:1009 (Editorial)

Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients (Gershwin et al). 2005;42:1194-1202

Progressive familial intrahepatic cholestasis

Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42: 242 (Correction)

Vagaries of impaired transporter function in PFIC 2 and 3 (Ostrow and Tiribelli). 2005;42:977-978 (Correspondence)

Vagaries of impaired transporter function in PFIC 2 and 3 (Keitel et al). 2005;42:978 (Reply)

Prostaglandin E_2 receptor

Significance and therapeutic potential of prostaglandin E_2 receptor in hepatic ischemia/reperfusion injury in mice (Kuzumoto et al). 2005;42:608-617

Proteasome

A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome (Anan and Gores). 2005;42:527-529 (Editorial)

Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL (Ganten et al). 2005;42:588-597

Proteomics

A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease (Younossi et al). 2005;42: 665-674

Hepatology Highlights (Elias). 2005;42: 513

Pulse

Assessment of liver fibrosis: palpate, poke or pulse? (Ghany and Doo). 2005; 42:759-761 (Editorial)

Q

Quality of health care
Determining the extent of quality health care for hospitalized patients with cirrhosis (Talwalkar). 2005;42:492-494 (Hepatology *Elsewhere*)
Quality of life
Hepatology Highlights (Elias). 2005;42:512
Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy (Campbell et al). 2005;42:635-640

R

Reactive oxygen species
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207
NADPH oxidase-dependent reactive oxygen species are important to the early stage of CD95 engagement in hepatocytes (Yin). 2005;42:956-958 (Hepatology *Elsewhere*)
Rejection
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005;42:208-215
Required for chromosomal-region-maintenance 1
Role of HSP90, CDC37, and CRM1 as modulators of $p16^{INK4A}$ activity in rat liver carcinogenesis and human liver cancer (Pascale et al). 2005;42:1310-1319
Research opportunities
Research opportunities on alcohol and liver damage (Zakhari and Hoofnagle). 2005;42:1243 (This Month From NIH)
Retrovirus
Successful gene therapy of the Gunn rat by in vivo neonatal hepatic gene transfer using murine oncoretroviral vectors (Bellodi-Privato et al). 2005;42:431-438
Ribavirin
Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics (González-Peralta et al). 2005;42:1010-1018
Ribosomal S6 kinase
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207
RNA, short interfering
Hepatology Highlights (Alter). 2005;42:1-2

S

Saturated fat
Hepatology Highlights (Kaplowitz). 2005;42:985-986
Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice (You et al). 2005;42:568-577
Schiff, Moritz
The biliary cycle of Moritz Schiff (Reuben). 2005;42:500-505 (Landmarks in Hepatology)
Scotland
Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland (Hutchinson, Bird, and Goldberg). 2005;42:711-723
Seeff, Leonard B.
AASLD 2005 Distinguished Service Award to Dr. Leonard B. Seeff (Hoofnagle). 2005;42:1246-1247 (2005 AASLD Awardees)
Serum alanine aminotransferase
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42:1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005;42:1461 (Reply)
Serum caspase
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum (Seidel et al). 2005;42:113-120
Signal transducers and activators of transcription STAT3
Interleukin 6 upregulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma cells (Isomoto et al). 2005;42:1329-1338
Single nucleotide polymorphisms
Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C (Kato et al). 2005;42:846-853
Sinusoidal endothelial cells
Hepatic targeting of transplanted liver sinusoidal endothelial cells in intact mice (Benten et al). 2005;42:140-148
Sinusoidal endothelium
Age-related changes in the hepatic sinusoidal endothelium impede lipoprotein transfer in the rat (Hilmer et al). 2005;42:1349-1354
Small gallstones
Small gallstones and pancreatitis (Costi et al). 2005;42:736 (Correspondence)
Small gallstones and pancreatitis (Venneman and van Erpecum). 2005;42:736-737 (Reply)
Smoking, cannabis
Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C (Hézode et al). 2005;42:63-71
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Schwabe and Siegmund). 2005;42:975-976 (Correspondence)
Potential role of CB2 receptors in cannabis smokers with chronic hepatitis C (Mallat, Hezode, and Lotersztajn). 2005;42:976-977 (Reply)
α-Smooth muscle actin
Intrahepatic gene expression profiles and alpha-smooth muscle actin patterns in hepatitis C virus induced fibrosis. 2005;42:273-281
Smooth pursuit eye movements
Disruption of smooth pursuit eye movements in cirrhosis: relationship to hepatic encephalopathy and its treatment (Montagnese et al). 2005;42:772-781
***S*-nitroso-*N*-acetyl-D,L-penicillamine**
Glutathione depletion renders rat hepatocytes sensitive to nitric oxide donor-mediated toxicity (Chen et al). 2005;42:598-607
Sodium/taurocholate cotransporter
Expression and localization of hepatobiliary transport proteins in progressive familial intrahepatic cholestasis (Keitel et al). 2005;42:242 (Correction)
Sphingosine kinase
Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver (Osawa et al). 2005;42:1320-1328
Staging systems
Comparison of staging systems for HCC: one more positive answer or mission impossible? (Huo, Wu, and Lee). 2005;42:238-239 (Correspondence)
Staging of hepatocellular carcinoma (Pawlik et al). 2005;42:738-739 (Correspondence)
Staging of hepatocellular carcinoma (Marrero et al). 2005;42:739-740 (Reply)
Starch
Hepatology Highlights (Elias). 2005;42:512-513
Steatohepatitis
Steatohepatitis induced by intragastric overfeeding in mice (Deng et al). 2005;42:905-914
Steatohepatitis, nonalcoholic
Adipokines in NASH: postprandial lipid

metabolism as a link between adiponectin and liver disease (Musso et al). 2005;42:1175-1183
Hepatology Highlights (Elias). 2005;42: 513, 1241

Steatosis
Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice (Yu et al). 2005;42: 362-371
Endocannabinoids promote hepatic lipogenesis and steatosis through CB1 receptors (Schwabe). 2005;42: 959-961 (Hepatology *Elsewhere*)
The extent of liver steatosis in chronic hepatitis C virus infection is mirrored by caspase activity in serum (Seidel et al). 2005;42:113-120
Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection (Monto et al). 2005;42:310-316
Hepatology Highlights (Alter). 2005;42: 2
Steatosis: co-factor in other liver diseases (Powell et al). 2005;42:5-13 (Perspectives in Clinical Hepatology)

Stellate cells
Early response of α2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-β independent (Svegliati-Baroni et al). 2005;42: 343-352
Fibroblast activation protein increases apoptosis, cell adhesion, and migration by the LX-2 human stellate cell line (Wang et al). 2005; 42:935-945
Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat (Benten et al). 2005;42: 1072-1081
rAAV-mediated stable expression of heme oxygenase-1 in stellate cells: a new approach to attenuate liver fibrosis in rats (Tsui et al). 2005;42: 335-342
Upregulation of proinflammatory and proangiogenic cytokines by leptin in human hepatic stellate cells (Aleffi et al). 2005;42:1339-1348

Stem cells
Recapitulation of in vivo gene expression during hepatic differentiation from murine embryonic stem cells (Yamamoto et al). 2005;42:558-567

Steroid transport
OSTα-OSTβ: a major basolateral bile acid and steroid transporter in human intestinal, renal, and biliary epithelia (Ballatori et al). 2005;42: 1270-1279

Stress, oxidative
Cytoplasmic retention of peroxide-activated ERK provides survival in primary cultures of rat hepatocytes (Rosseland et al). 2005;42:200-207

Syndromes of intrahepatic cholestasis
Intrahepatic cholestasis: summary of an American Association for the Study of Liver Diseases single-topic conference (Balistreri et al). 2005; 42:222-235 (Special Article)

T

T cells
CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice (Moreno et al). 2005;42:854-862
Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C (Cox et al). 2005;42:104-112
Conventional liver CD4 T cells are functionally distinct and suppressed by environmental factors (Katz et al). 2005;42:293-300
Early intrahepatic antigen-specific retention of naive $CD8^+$ T cells is predominantly ICAM-1/LFA-1 dependent in mice (Bertolino et al). 2005;42:1063-1071
Intrahepatic $CD8^+$ T-cell failure during chronic hepatitis C virus infection (Spangenberg et al). 2005;42:828-837
Murine liver antigen presenting cells control suppressor activity of $CD4^+CD25^+$ regulatory T cells (Wiegard et al). 2005;42:193-199

T cells, helper
Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis (Muñoz et al). 2005;42:411-419

TCPOBOP
Hepatology Highlights (Alter). 2005;42: 247-248

Telomere shortening
Telomere shortening correlates with increasing aneuploidy of chromosome 8 in human hepatocellular carcinoma (Plentz et al). 2005;42:522-526 (Rapid Communication)

Tenofovir
Reactivation of viral replication after replacement of tenofovir by adefovir (van Bömmel and Berg). 2005;42: 239-240 (Correspondence)

Tie-2, soluble (sTie-2)
The potential of angiogenesis soluble markers in chronic hepatitis C (Salcedo et al). 2005;42:696-701

Tissue transglutaminase
Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice (Sarang et al). 2005;42:578-587

Toll-like 3 receptor
Hepatology Highlights (Alter). 2005;42: 1

Toll-like receptor
Altered monocyte responses to defined TLR ligands in patients with primary biliary cirrhosis (Mao et al). 2005;42:802-808

Transforming growth factor β
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells (Herzer et al). 2005;42:183-192

Transforming growth factor β1
Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934

Transjugular intrahepatic portal-systemic shunt
Hepatology Highlights (Elias). 2005;42: 512
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Libbrecht et al). 2005;42:236 (Correspondence)
Influence of TIPS on development of hepatocellular carcinoma in cirrhosis (Bañares and Núñez). 2005;42:236-237 (Reply)
Quality of life in refractory ascites: dtransjugular intrahepatic portal-systemic shunting versus medical therapy (Campbell et al). 2005;42: 635-640
TIPS for veno-occlusive disease: Is the contraindication real? (Senzolo et al). 2005;42:240-241 (Correspondence)
TIPS for veno-occlusive disease: Is the contraindication real? (Boyer). 2005;42:241 (Reply)

Transplantation. *See* Hepatocyte transplantation; Liver transplantation

Tumor growth
Telomerase antagonists GRN163 and GRN163L inhibit tumor growth and increase chemosensitivity of human hepatoma (Djojosubroto et al). 2005;42:1127-1136

Tumor necrosis factor
Adenoviral gene transfer of ABIN-1 protects mice from TNF/galactosamine-induced acute liver failure and lethality (Wullaert et al). 2005;42:381-389

Tumor necrosis factor α
Alcohol increases tumor necrosis factor α and decreases nuclear factor-κB to activate hepatic apoptosis in genetically obese mice (Robin et al). 2005;42:1280-1290

Mesenteric Th1 polarization and monocyte TNF-α production: first steps to systemic inflammation in rats with cirrhosis (Muñoz et al). 2005;42:411-419
Oxidative mitochondrial DNA damage and deletion in hepatocytes of rejecting liver allografts in rats: role of TNF-α (Nagakawa et al). 2005; 42:208-215

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)
A new TRAIL to therapy of hepatocellular carcinoma: blocking the proteasome (Anan and Gores). 2005;42:527-529 (Editorial)
Oral adeno-associated virus-sTRAIL gene therapy suppresses human hepatocellular carcinoma growth in mice (Ma et al). 2005;42:1355-1363
Proteasome inhibition sensitizes hepatocellular carcinoma cells, but not human hepatocytes, to TRAIL (Ganten et al). 2005;42:588-597
Transforming growth factor β can mediate apoptosis via the expression of TRAIL in human hepatoma cells (Herzer et al). 2005;42:183-192

Tumors
Genotype-phenotype relationships in hepatocellular tumors from mice and man (Stahl et al). 2005;42:353-361

U

UDP-glucuronosyltransferase
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Dietrich and Geier). 2005;42:1462 (Correspondence)
It takes more than one—Is a single UGT polymorphism enough to bother detoxification? (Guillemette and Girard). 2005;42:1463 (Reply)
UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver (Girard et al). 2005;42:448-457

United States
Hepatitis C virus load and survival among injection drug users in the United States (Hisada et al). 2005; 42:1446-1452
Trends in health care resource use for hepatitis C virus infection in the United States (Grant et al). 2005; 42:1406-1413

Ursodeoxycholic acid
Hepatology Highlights (Elias). 2005;42: 1241-1242, 1242
Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid (Glantz et al). 2005;42:1399-1405
Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis (Combes et al). 2005;42: 1184-1193
Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-β1-induced apoptosis in rat hepatocytes (Solá et al). 2005;42:925-934

V

V162del ferroportin disease
Primary iron overload with inappropriate hepcidin expression in V162del ferroportin disease (Zoller et al). 2005;42:466-472

Vaccination
A functional polymorphism in the *IL-10* promoter influences the response after vaccination with HBsAg and hepatitis A (Höhler et al). 2005;42: 72-76
Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination (Shim et al). 2005;42:688-695

Vascular endothelial growth factor
The potential of angiogenesis soluble markers in chronic hepatitis C (Salcedo et al). 2005;42:696-701

Vascularity
Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma (Bolondi et al). 2005;42: 27-34

Vasoactive intestinal peptide receptor-1
VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium (Chignard et al). 2005; 42:549-557

Veno-occlusive disease
TIPS for veno-occlusive disease: Is the contraindication real? (Senzolo et al). 2005;42:240-241 (Correspondence)
TIPS for veno-occlusive disease: Is the contraindication real? (Boyer). 2005;42:241 (Reply)

Viperin
Analysis of ISG expression in chronic hepatitis C identifies viperin as a potential antiviral effector (Helbig et al). 2005;42:702-710

Virus-like particles, cell-permeable
A novel system for efficient gene transfer into primary human hepatocytes via cell-permeable hepatitis B virus-like particle (Brandenburg et al). 2005; 42:1300-1309

Vitamin A
Comparison of indices of vitamin A status in children with chronic liver disease (Feranchak et al). 2005;42: 782-792
Hepatology Highlights (Elias). 2005;42: 1242

Volume expanders
Volume expanders for spontaneous bacterial peritonitis: Are we comparing oranges with oranges? (Wong). 2005;42:533-535 (Editorial)

W

Weight loss surgery
Morbid obesity, nonalcoholic fatty liver disease, and weight loss surgery (Srivastava and Younossi). 2005;42: 490-492 (Hepatology *Elsewhere*)

Wilson disease
Wilson disease—Keeping the bar for diagnosis raised (Perri et al). 2005; 42:974 (Correspondence)

Women's health
Hepatology Highlights (Elias). 2005;42: 1242
Intrahepatic cholestasis of pregnancy and bile acid levels (Sentilhes et al). 2005;42:737-738 (Correspondence)
Intrahepatic cholestasis of pregnancy and bile acid levels (Glantz, Marschall, and Mattsson). 2005;42:738 (Reply)
Of mice and women: toward a mouse model of autoimmune hepatitis (Heneghan and McFarlane). 2005; 42:17-20 (Editorial)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Kunde et al). 2005; 42:650-656
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Prati et al). 2005;42: 1460-1461 (Correspondence)
Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women (Abrams et al). 2005; 42:1461 (Reply)